<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        22-262-12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ATOZET 10/40 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ATORVASTATIN CALCIUM,EZETIMIBE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10,40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        135.10
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MSD International GmbH (PUERTO RICO Branch)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MSD International GmbH (PUERTO RICO Branch)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Organon Pharma UK Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10BA05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p>ATOZET is a medicine to lower increased levels of cholesterol. ATOZET contains ezetimibe and atorvastatin.</p><p>&nbsp;</p><p>ATOZET is used in adults to lower levels of total cholesterol, &ldquo;bad&rdquo; cholesterol (LDL cholesterol), and fatty substances called triglycerides in the blood. In addition, ATOZET raises levels of &ldquo;good&rdquo; cholesterol (HDL cholesterol).</p><p>&nbsp;</p><p>ATOZET works to reduce your cholesterol in two ways. It reduces the cholesterol absorbed in your digestive tract, as well as the cholesterol your body makes by itself.</p><p>&nbsp;</p><p>Cholesterol is one of several fatty substances found in the bloodstream. Your total cholesterol is made up mainly of LDL and HDL cholesterol.</p><p>&nbsp;</p><p>LDL cholesterol is often called &ldquo;bad&rdquo; cholesterol because it can build up in the walls of your arteries forming plaque. Eventually this plaque build-up can lead to a narrowing of the arteries. This narrowing can slow or block blood flow to vital organs such as the heart and brain. This blocking of blood flow can result in a heart attack or stroke.</p><p>&nbsp;</p><p>HDL cholesterol is often called &ldquo;good&rdquo; cholesterol because it helps keep the bad cholesterol from building up in the arteries and protects against heart disease.</p><p>&nbsp;</p><p>Triglycerides are another form of fat in your blood that may increase your risk for heart disease. ATOZET is used for patients who cannot control their cholesterol levels by diet alone. You should stay on a cholesterol-lowering diet while taking this medicine.</p><p>&nbsp;</p><p>ATOZET is used in addition to your cholesterol-lowering diet if you have:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a raised cholesterol level in your blood (primary hypercholesterolaemia [heterozygous familial and non-familial]) or elevated fat levels in your blood (mixed hyperlipidaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; that is not well controlled with a statin alone;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for which you have used a statin and ezetimibe as separate tablets.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a hereditary illness (homozygous familial hypercholesterolaemia) that increases the cholesterol level in your blood. You may also receive other treatments.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart disease. ATOZET reduces the risk of heart attack, stroke, surgery to increase heart blood flow, or hospitalisation for chest pain.</p><p>&nbsp;</p><p>ATOZET does not help you lose weight.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if !supportLists]--></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take ATOZET if</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic to ezetimibe, atorvastatin or any of the other ingredients of this medicine (listed in section 6)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have or have ever had a disease that affects the liver</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have had any unexplained abnormal blood tests for liver function</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are a woman able to have children and are not using reliable contraception</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are pregnant, trying to become pregnant or are breast-feeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you use the combination of glecaprevir/pibrentasvir in the treatment of hepatitis C.</p><p>&nbsp;</p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before taking ATOZET if</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have had a previous stroke with bleeding into the brain, or have small pockets of fluid in the brain from previous strokes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have an under-active thyroid gland (hypothyroidism)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have had repeated or unexplained muscle aches or pains, a personal history or family history of muscle problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have had previous muscular problems during treatment with other lipid-lowering medicines (e.g. other &ldquo;statin&rdquo; or &ldquo;fibrate&rdquo; medicines)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you regularly drink a large amount of alcohol</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a history of liver disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are older than 70 years</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this product</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are taking or have taken in the last 7 days a medicine called fusidic acid, (a medicine for bacterial infection) orally or by injection. The combination of fusidic acid and ATOZET can lead to serious muscle problems (rhabdomyolysis)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Contact your doctor promptly if you experience unexplained muscle pain, tenderness, or weakness while taking ATOZET. </strong>This is because on rare occasions, muscle problems can be serious, including muscle breakdown resulting in kidney damage. Atorvastatin is known to cause muscle problems, and cases of muscle problems have also been reported with ezetimibe.</p><p>&nbsp;</p><p>Also tell your doctor or pharmacist if you have a muscle weakness that is constant. Additional tests and medicines may be needed to diagnose and treat this.</p><p>&nbsp;</p><p>Check with your doctor or pharmacist before taking ATOZET:</p><p>&minus; if you have severe respiratory failure.</p><p>&nbsp;</p><p>If any of these apply to you (or you are not sure), talk to your doctor or pharmacist before taking ATOZET because your doctor will need to carry out a blood test before and possibly during your ATOZET treatment to predict your risk of muscle-related side effects. The risk of muscle-related side effects, e.g. rhabdomyolysis, is known to increase when certain medicines are taken at the same time (see section 2 &ldquo;Other medicines and ATOZET&rdquo;).</p><p>&nbsp;</p><p>While you are on this medicine your doctor will monitor you closely if you have diabetes or are at risk of developing diabetes. You are likely to be at risk of developing diabetes if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure.</p><p>&nbsp;</p><p>Tell your doctor about all your medical conditions including allergies.</p><p>&nbsp;</p><p>The combined use of ATOZET and fibrates (medicines for lowering cholesterol) should be avoided since the combined use of ATOZET and fibrates has not been studied.</p><p>&nbsp;</p><p>Children</p><p>ATOZET is not recommended for children and adolescents.</p><p>&nbsp;</p><p>Other medicines and ATOZET</p><p>Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including those obtained without prescription.</p><p>&nbsp;</p><p>There are some medicines that may change the effect of ATOZET or their effect may be changed by ATOZET (see section 3). This type of interaction could make one or both of the medicines less effective. Alternatively it could increase the risk or severity of side effects, including the important muscle wasting condition known as &ldquo;rhabdomyolysis&rdquo; described in section 4:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ciclosporin (a medicine often used in organ transplant patients)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; erythromycin, clarithromycin, telithromycin, fusidic acid,** rifampicin (medicines for bacterial infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ketoconazole, itraconazole, voriconazole, fluconazole, posaconazole (medicines for fungal infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gemfibrozil, other fibrates, nicotinic acid, derivatives, colestipol, cholestyramine (medicines for regulating lipid levels)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some calcium channel blockers used for angina or high blood pressure, e.g., amlodipine, diltiazem</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; digoxin, verapamil, amiodarone (medicines to regulate your heart rhythm)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used in the treatment of HIV, e.g., ritonavir, lopinavir, atazanavir, indinavir, darunavir, the combination of tipranavir/ritonavir, etc. (medicines for AIDS)</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines used in the treatment of hepatitis C, e.g., telaprevir, boceprevir and the combination of elbasvir/grazoprevir</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; daptomycin (a medicine used to treat complicated skin and skin structure infections and bacteraemia).</p><p>&nbsp;</p><p>**If you need to take oral fusidic acid to treat a bacterial infection you will need to temporarily stop using this medicine. Your doctor will tell you when it is safe to restart ATOZET. Taking ATOZET with fusidic acid may rarely lead to muscle weakness, tenderness or pain (rhabdomyolysis). See more information regarding rhabdomyolysis in section 4.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other medicines known to interact with ATOZET</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oral contraceptives (medicines for preventing pregnancy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stiripentol (an anticonvulsant medicine for epilepsy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cimetidine (a medicine used for heartburn and peptic ulcers)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenazone (a painkiller)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antacids (indigestion products containing aluminium or magnesium)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; warfarin, phenprocoumon, acenocoumarol or fluindione (medicines to prevent blood clots)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; colchicine (used to treat gout)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St John&#39;s wort (a medicine to treat depression)</p><p>&nbsp;</p><p>ATOZET with food and alcohol</p><p>See section 3 for instructions on how to take ATOZET. Please note the following:</p><p>&nbsp;</p><p><em>Grapefruit juice</em></p><p>Do not take more than one or two small glasses of grapefruit juice per day because large quantities of grapefruit juice can change the effects of ATOZET.</p><p>&nbsp;</p><p><em>Alcohol</em></p><p>Avoid drinking too much alcohol while taking this medicine. See section 2 &ldquo;Warnings and precautions&rdquo; for details.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p>Do not take ATOZET if you are pregnant, are trying to get pregnant or think you may be pregnant. Do not take ATOZET if you are able to become pregnant unless you use reliable contraceptive measures. If you get pregnant while taking ATOZET, stop taking it immediately and tell your doctor.</p><p>&nbsp;</p><p>Do not take ATOZET if you are breast-feeding.</p><p>&nbsp;</p><p>The safety of ATOZET during pregnancy and breast-feeding has not yet been proven. Ask your doctor or pharmacist for advice before taking this medicine.</p><p>Driving and using machines</p><p>ATOZET is not expected to interfere with your ability to drive or to use machinery. However, it should be taken into account that some people may get dizzy after taking ATOZET.</p><p>&nbsp;</p><p>ATOZET contains lactose</p><p>ATOZET tablets contain a sugar called lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>&nbsp;</p><p><strong>ATOZET contains sodium </strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Your doctor will determine the appropriate tablet strength for you, depending on your current treatment and your personal risk status. Check with your doctor or pharmacist if you are not sure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before starting ATOZET, you should be on a diet to lower your cholesterol.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should keep on this cholesterol-lowering diet while taking ATOZET.</p><p>&nbsp;</p><p><u>How much to take</u></p><p>The recommended dose is one ATOZET tablet by mouth once a day.</p><p>&nbsp;</p><p><u>When to take</u></p><p>Take ATOZET at any time of the day. You can take it with or without food.</p><p>&nbsp;</p><p>If your doctor has prescribed ATOZET along with cholestyramine or any other bile acid sequestrant (medicines for lowering cholesterol), you should take ATOZET at least 2 hours before or 4 hours after taking the bile acid sequestrant.</p><p>&nbsp;</p><p>If you take more ATOZET than you should</p><p>Please contact your doctor or pharmacist.</p><p>&nbsp;</p><p>If you forget to take ATOZET</p><p>Do not take an extra dose; just take your normal amount of ATOZET at the usual time the next day. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, ATOZET can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>If you experience any of the following serious side effects or symptoms, stop taking your tablets and tell your doctor immediately or go to the nearest hospital accident and emergency department.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious allergic reaction which causes swelling of the face, tongue and throat that can cause great difficulty in breathing</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious illness with severe peeling and swelling of the skin, blistering of the skin, mouth, eyes genitals and fever; skin rash with pink-red blotches especially on palms of hands or soles of feet, which may blister</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle weakness, tenderness,pain or rupture or red-brown discolouration of urine and particularly, if at the same time, you feel unwell or have a high temperature it may be caused by an abnormal muscle breakdown which can be life-threatening and lead to kidney problems</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lupus-like disease syndrome (including rash, joint disorders and effects on blood cells)</p><p>&nbsp;</p><p>You should consult your doctor as soon as possible if you experience problems with unexpected or unusual bleeding or bruising, because this may be suggestive of a liver complaint.</p><p>&nbsp;</p><p>The following common side effects were reported (may affect up to 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle aches</p><p>&nbsp;</p><p>The following uncommon side effects were reported (may affect up to 1 in 100 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the flu</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression; trouble sleeping; sleep disorder</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness; headache; tingling sensation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; slow heart beat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hot flush</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain; abdominal bloating; constipation; indigestion; flatulence; frequent bowel movements; inflammation of the stomach; nausea; stomach discomfort; upset stomach</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acne; hives</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain; back pain; leg cramps; muscle fatigue, spasms, or weakness; pain in arms and legs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual weakness; feeling tired or unwell; swelling especially in the ankles (oedema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; elevations in some laboratory blood tests of liver or muscle (CK) function</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight gain</p><p>&nbsp;</p><p>Additionally, the following side effects have been reported in people taking ATOZET, or ezetimibe or atorvastatin tablets:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions including swelling of the face, lips, tongue, and/or throat that may cause difficulty in breathing or swallowing (which requires treatment immediately)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; raised red rash, sometimes with target-shaped lesions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heartburn</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased appetite; loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash and itching; allergic reactions including rash and hives</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tendon injury</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gallstones or inflammation of the gallbladder (which may cause abdominal pain, nausea, vomiting)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas often with severe abdominal pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduction in blood cell counts, which may cause bruising/bleeding (thrombocytopenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the nasal passages; nose bleed</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; neck pain; pain; chest pain; pain in the throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increases and decreases in blood sugar levels (if you have diabetes you should continue careful monitoring of your blood sugar levels)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; having nightmares</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; numbness or tingling in the fingers and toes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduction of sensation to pain or touch</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in sense of taste; dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of memory</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ringing in the ears and/or head; hearing loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; belching</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; raised temperature</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urine tests that are positive for white blood cells</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision; visual disturbances</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gynaecomastia (breast enlargement in men).</p><p>&nbsp;</p><p>Possible side effects reported with some statins</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sexual difficulties</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathing problems including persistent cough and/or shortness of breath or fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diabetes. This is more likely if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure. Your doctor will monitor you while you are taking this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain, tenderness, or weakness that is constant and particularly if, at the same time, you feel unwell or have a high temperature that may not go away after stopping ATOZET (frequency not known).</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (Via The National Pharmacovigilance and Drug Safety Centre (NPC) SFDA). By reporting side effects, you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&deg; C</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;Store in the original package in order to protect from oxygen.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take ATOZET after the expiry date stated on the carton or container after &ldquo;EXP.&rdquo;</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What ATOZET contains</p><p>The active substances are ezetimibe and atorvastatin. Each film-coated tablet contains 10 mg ezetimibe and 10 mg, 20 mg, 40 mg, or 80 mg atorvastatin (as atorvastatin calcium trihydrate).</p><p>&nbsp;</p><p>The other ingredients are: calcium carbonate; silica, colloidal anhydrous; croscarmellose sodium; hydroxypropylcellulose; lactose monohydrate; magnesium stearate; cellulose, microcrystalline; polysorbate 80; povidone; sodium laurilsulphate.</p><p>&nbsp;</p><p>The film coating contains: hypromellose, macrogol 8000, titanium dioxide (E171), talc.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Capsule-shaped, biconvex, film-coated tablets, white to off white.
 
ATOZET 10 mg/10 mg tablets: “257” debossed on one side ATOZET 10 mg/20 mg tablets: “333” debossed on one side ATOZET 10 mg/40 mg tablets: “337” debossed on one side

Pack sizes:
Packs of 10, 30, 90, and 100 film-coated tablets in nitrogen-purged aluminium/aluminium (oPA-Al-PVC cavity with Al lidding) blisters.

Packs of 30 x 1 and 45 x 1 film-coated tablets in unit dose, nitrogen-purged aluminium/aluminium (oPA- Al-PVC cavity with Al lidding) blisters.

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p><strong>Marketing Authorization Holder</strong> Merck Sharp &amp; Dohme Ltd Hertford Road,</p><p>Hoddesdon Hertfordshire EN11 9BU</p><p>&nbsp; United Kingdom</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>MSD International GmbH (Puerto Rico Branch) LLC,</p><p>State Road 183, PRIDCO Industrial Park,</p><p>Las Piedras, Puerto Rico 00771</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in March 2020 

To report any side effect(s):
•	Saudi Arabia: 
The National Pharmacovigilance Centre (NPC):
SFDA Call Center: 19999
E-mail: npc.drug@sfda.gov.sa
Website: https://ade.sfda.gov.sa

•	Other GCC States: 
Please contact the relevant competent authority.


This is a Medicament
	Medicament  is  a  product  which  affects  your  health  and  its  consumption  contrary  to instructions is dangerous for you.
	Follow strictly the doctor’s prescription, the method of use and the instructions  of the pharmacist who sold the medicament.
	The doctor and the pharmacist are the experts in medicines, their benefits and risks.
	Do not by yourself interrupt the period of treatment prescribed for you.
	Do not repeat the same prescription without consulting your doctor.
	Keep all medicaments out of reach of children.

Council of Arab Health Ministers  
 Union of Arab Pharmacists

This patient information leaflet is approved by the Saudi Food & Drug Authority. 


            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">أتوزت دواء لخفض مستويات الكوليسترول المرتفعة. يحتوي أتوزت على مادتين فعالتين هما ايزيتيمايب و أتورفاستاتين .</p><p dir="RTL">يعمل أتوزت لدى البالغين على خفّض مستوى الكوليسترول الكُلي، الكوليسترول السيء (البروتين ُالشَّحْمِيُّ المنخفض الكَثافة) والمواد الدهنيّة المعروفة بالدهون الثلاثية في الدم. اضافة إلى ذلك، يرفع من مستويات الكوليسترول الجيّد (البروتين ُالشَّحْمِيُّ المُرْتَفِعُ الكَثافَة).</p><p dir="RTL">يعمل أتوزت على خفض الكوليسترول بطريقتين. حيث يعمل على خفض الكوليسترول الذي يتم امتصاصه في القناة الهضمية وكذلك الكوليسترول الذي ينتجه الجسم.</p><p dir="RTL">يُعتبَر الكوليسترول واحدًا من المواد الدهنيّة العديدة في مجرى الدم. الكولسترول الكُلي مؤلّف بشكل أساسي من الكوليسترول السيء (البروتين&nbsp; الشَّحْمِيُّ&nbsp; المنخفض الكَثافة) و الكوليسترول الجيّد (البروتين&nbsp; الشَّحْمِيُّ المُرْتَفِعُ الكَثافَة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">غالبًا ما يُعرَف الكوليسترول (البروتين ُالشَّحْمِيُّ المنخفض الكَثافة) بالكوليسترول السيء لأنّه يتكدّس في جدران شرايينك فيشكّل لويحة قد تُضيّق مجاري الشرايين، ممّا قد يُبطئ تدفّق الدم أو يُعرقله فيمنع وصوله إلى الأعضاء الحيويّة، مثل القلب والدماغ. قد يُسبّب انسداد تدفّق الدم إلى سكتة أو نوبة قلبيّة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أما الكوليسترول (البروتين ُالشَّحْمِيُّ المُرْتَفِعُ الكَثافَة) فغالبًا ما يُعرَف بالكوليسترول الجيّد لأنّه يُساهم في منع الكوليسترول السيء من التكدّس في الشرايين ويحمي من أمراض القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الدهون الثلاثية شكل آخر من المواد الدهنيّة في دمك التي قد تزيد من خطر تعرّضك لأمراض قلبيّة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدَم أتوزت&nbsp; لدى المرضى الذين لا يُمكنهم السيطرة على مستويات الكوليسترول من خلال مجرّد حمية غذائيّة مخّفضة للكوليسترول. عليك الابقاء على الحمية المُخفِّضة للكوليسترول عندما تتناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم أتوزت إلى جانب النظام الغذائي المخفض للكوليسترول في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ارتفاع مستوى الكوليسترول في الدم (فرط كوليسترول الدم الرئيسي [متغاير الزيجوت العائلي وغير العائلي]) أو ارتفاع مستويات الدهون في الدم (فرط شحميات الدم المختلطة) .</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عندما لا تتمّ السيطرة بشكل جيّد على مستوى الكولسترول بواسطة مادة الستاتين وحدها</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدمت لعلاجه الإستاتين و ايزيتيمايب كأقراص منفصلة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض وراثي (فرط كولسترول الدم العائلي المتماثل الزيجوت) يزيد من مستوى الكولسترول في الدم. قد توصف لك مادة الستاتين وقد تتلقّى علاجات أخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض في القلب، فإن أتوزت يعمل على تقليل خطر الإصابة بالنوبات القلبية والسكتة الدماغية، و الحاجة إلى عملية جراحية لزيادة تدفق الدم من القلب، أو دخول المستشفى لعلاج آلام الصدر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يُساعدك أتوزت على فقدان الوزن.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تستخدم أتوزت في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فرط الحساسية من ايزيتيمايب أو أتورفاستاتين أو أيٍ من المكونات الأخرى في هذا الدواء (المذكورة في القسم 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني حاليًا - أو سابقًا - من مرض يؤثر في الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أجريت اختبارات لوظائف الكبد وكانت نتائجها مرتفعة بسبب مجهول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان المريض أنثى قادرة على الإنجاب ولا تستخدم وسائل منع الحمل الموثوق بها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملًا، أو تُحاولين الحمل، أو مُرضعًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك استخدام مزيج من جليكابريفير / بيبنتازفير في علاج التهاب الكبد ج</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المخاطر و الاحتياطات </strong></p><p dir="RTL">ينبغي استشارة الطبيب أو الصيدلي قبل استخدام أتوزت في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أُصبت بسكتة سابقًا مع نزيف دماغي، أو تعاني من جيوب صغيرة من السوائل في الدماغ نتيجة سكتات سابقة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات في الكُلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من قصور نشاط الغدة الدرقية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من آلام عضلية متكررة أو مجهولة السبب أو لديك تاريخ شخصي أو عائلي من المشكلات العضلية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أُصبت بمشكلات عضلية سابقة أثناء العلاج بأدوية أخرى مخفضة للدهون (مثل أدوية أخرى من فئة &quot;الإستاتين&quot; أو &quot;الفيبرات&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتعاطى الكحول بكميات كبيرة وبصفة معتادة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ لمرض كبدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان سنك أكبر من 70 سنة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان الطبيب قد أخبرك أنك لا تتحمل بعض أنواع السكر، فاتصل بالطبيب قبل تناول هذا الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أو اسخدمت في آخر 7 أيام دواء يسمى حمض الفوسيديك (دواء للعدوى البكتيرية) عن طريق الفم أو عن طريق الحقن. مزيج حمض الفوسيديك و الأتوزت يمكن أن يؤدي إلى مشاكل خطيرة في العضلات (انحلال الربيدات)</p><p dir="RTL">&nbsp;</p><p dir="RTL">اخبر الطبيب على الفور إذا شعرت بألم أو حساسيّة عند اللمس أو ضعف مجهول السبب في العضلات أثناء استخدام أتوزت. هذا لأنه في حالات نادرة؛ يمكن أن تكون مشكلات العضلات خطيرة بما في ذلك انهيار العضلات الذي يؤدي إلى تلف الكليتين. من المعروف أن العقار أتورفاستاتين يسبب مشكلات في العضلات؛ وقد وردت تقارير عن مشكلات في العضلات مع استخدام العقار ايزيتيمايب أيضًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي أيضًا إذا كان لديك ضعف عضلي ثابت. قد تكون هناك حاجة إلى اختبارات وأدوية إضافية لتشخيص هذا وعلاجه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي استشارة الطبيب أو الصيدلي قبل تناول أقراص أتوزت في الحالات التالية:</p><p dir="RTL">&bull; إذا كنت تعاني من فشل تنفسي شديد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت هذه الحالة تنطبق عليك (أو لست متأكدًا من هذا)؛ فينبغي استشارة الطبيب أو الصيدلي قبل استخدام أتوزت؛ لأن الطبيب ينبغي أن يُجري لك اختبار دم قبل - ومن الممكن أثناء - العلاج بالعقار أتوزت لتقدير احتمال تعرضك لأعراض جانبية مرتبطة بالعضلات. من المعروف أن احتمال الإصابة بأعراض جانبية مرتبطة بالعضلات - مثل انحلال الربيدات - يزيد مع استخدام أدوية معينة في الوقت نفسه (انظر البند 2 &quot;الأدوية الأخرى وأتوزت&quot;).</p><p dir="RTL">أثناء استخدامك لهذا الدواء؛ سيقوم الطبيب بمراقبة حالتك عن قرب إذا كنت مصابًا بداء السُّكَري أو معرضًا للإصابة به. من المحتمل تعرضك لخطر الإصابة بداء السكري إذا ارتفعت مستويات السكر والدهون في دمك وكنت بدينًا ومصابًا بضغط الدم المرتفع.</p><p dir="RTL">ينبغي إخبار الطبيب عن جميع الحالات الطبية التي تعاني منها بما في ذلك الحساسيّة.</p><p dir="RTL">ينبغي تجنب استخدام أتوزت بالتزامن مع الأدوية من فئة الفيبرات (أدوية مخفضة للكوليسترول) لأنّه لم تُجرَ دراسات على الاستخدام المتزامن لهذه الأدوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">لا يوصى باستخدام أتوزت في الأطفال والمراهقين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وأتوزت</strong></p><p dir="RTL">يُرجى إخبار الطبيب أو الصيدلي إذا كنت تتناول حاليًا - أو تناولت مؤخرًا - أيّ أدوية أخرى أو قد تتناولها مستقبلاً، بما في ذلك الأدوية التي تأخذها دون وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">توجد بعض الأدوية التي يمكن أن تغيِّر مفعول أتوزت أو قد يتغير مفعول تلك الأدوية بسبب أتوزت (انظر البند 3). ويمكن أن يؤدي هذا النوع من التفاعل إلى تقليل مفعول كلا الدوائين. أو قد يؤدي إلى زيادة احتمال الإصابة بأعراض جانبية أو زيادة شدتها؛ بما في ذلك حالة هزال العضلات المعروفة بـ &quot;انحلال الربيدات&quot; المذكورة في البند 4:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين (دواء يُوصف غالبًا للمرضى الذين أُجريت لهم عمليات زرع أعضاء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إريثرومايسين، كلاريثرومايسين، تيليثرومايسين، حمض الفوسيديك**، ريفامبيسين (أدوية لعلاج الالتهابات الجرثوميّة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيتوكونازول، إتراكونازول، فوريكونازول، فلوكونازول، بوساكونازول (أدوية لعلاج الالتهابات الفطريّة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جيمفيبروزيل، أدوية أخرى من فئة الفيبرات، مشتقات حمض النيكوتين، كوليستيبول، كوليستيرامين (أدوية لضبط مستويات الدهون).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تُستخدم بعض الأدوية من فئة حاصرات قنوات الكالسيوم لعلاج الذبحة الصدرية أو ارتفاع ضغط الدم مثل أملوديبين، دلتيازيم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديجوكسين، فيرباميل، أميودارون (أدوية لضبط نظم القلب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج عدوى فيروس نقص المناعة البشرية مثل ريتونافير، لوبينافير، أتازنافير، إندينافير، دارونافير، تركيبة العقارين تيبرانافير/ريتونافير، إلخ (أدوية لعلاج الإيدز).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المستخدمة في علاج الالتهاب الكبدي ج؛ مثل تيلابريفير, بوسيبريفير و مزيج الباسفير \ قرازوبريفير.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دابتوميسين، (دواء يستخدم لعلاج الجلد المعقد والتهابات هيكل الجلد والجراثيم).</p><p dir="RTL">&nbsp;</p><p>** إذا كنت بحاجة إلى تناول حمض الفوسيديك عن طريق الفم لعلاج عدوى بكتيرية ، فستحتاج إلى التوقف مؤقتًا عن استخدام هذا الدواء. سيخبرك طبيبك متى يكون من الآمن تناول أتوزت. تناول أتوزت مع حمض الفوسيديك نادرًا ما يؤدي إلى ضعف العضلات ، حساسية عند اللمس أو الألم (انحلال الربيدات). انظر المزيد من المعلومات حول انحلال الربيدات في القسم 4.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>من الأدوية الأخرى المعروفة بالتفاعل مع أتوزت:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وسائل منع الحمل الفموية (أدوية لمنع الحمل).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستيريبنتول (دواء مضاد للاختلاجات لعلاج الصرع).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيميتدين (دواء لعلاج&nbsp; حموضة او حرقة في المعدة والقرحة الهضمية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينازون (مسكن للألم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الحموضة (أدوية لعلاج عسر الهضم محتوية على الألومنيوم أو الماغنيسيوم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وارفارين، فينبروكومون، أسينوكومارول أو فلويندوين (أدوية للوقاية من الجلطات الدموية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كولشيسين (لعلاج النقرس).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عشبة القديس يوحنا (دواء لعلاج الاكتئاب).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام أتوزت مع الأطعمة والكحول</strong></p><p dir="RTL">انظر البند 3 للاطلاع على التعليمات عن كيفية استخدام أتوزت. يُرجى ملاحظة التالي:</p><p dir="RTL"><u>عصير</u><u> </u><u>الليمون</u><u> </u><u>الهندي </u><u>&nbsp;)</u><u>الجريب</u><u> </u><u>فروت</u><u>(</u><u> </u></p><p dir="RTL">ينبغي عدم تناول أكثر من كوب واحد أو كوبين صغيرين من عصير الليمون الهندي في اليوم لأن الكميات الكبيرة منه يمكن أن تغير من مفعول أتوزت.</p><p dir="RTL"><u>الكحول </u></p><p dir="RTL">ينبغي تجنب الإفراط في تعاطي الكحول أثناء استخدام هذا الدواء. انظر البند 2 &quot; المخاطر و الاحتياطات &quot; لمعرفة التفاصيل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">لا تتناولي أتوزت إذا كنتِ حاملًا، أو تُحاولين الحمل، أو تظنّين أنّك قد تكونين حاملًا . يجب عدم استخدام أتوزت للمرأة القادرة على الإنجاب إلا إذا كانت تستخدم وسائل منع حمل موثوق بها. في حالة حدوث حمل أثناء استخدام أتوزت؛ يجب التوقف عن استخدامه فورًا وإعلام الطبيب بذلك.</p><p dir="RTL">يجب عدم استخدام أتوزت في حالة الرضاعة الطبيعية.</p><p dir="RTL">لم تثبت سلامة استخدام أتوزت أثناء الحمل والرضاعة حتى الآن.</p><p dir="RTL">يُرجى استشارة الطبيب أو الصيدلي قبل استخدام هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة و استخدام الآلات </strong></p><p dir="RTL">ليس من المتوقع أن يؤثر أتوزت على القدرة على قيادة المركبات أو استخدام الآلات. ولكن ينبغي مراعاة أن بعض الأشخاص قد يُصابون بدوار بعد استخدام أتوزت.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي أتوزت على اللاكتوز</strong></p><p dir="RTL">يحتوي أتوزت على مادة سكريّة تُعرَف باللاكتوز. في حال قال لك الطبيب بأنّك لا تحتمل بعض المواد السكريّة، عليك الإتصال بطبيبك قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي </strong><strong>أتوزت</strong><strong> على الصوديوم </strong></p><p dir="RTL">هذا الدواء يحتوي علي اقل من 1 ملليمول الصوديوم (23 ملغم) للقرص الواحد ، وهذا يعني بأنه أساسا &quot;خالٍ من الصوديوم</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ينبغي استخدام هذا الدواء دائمًا حسب إرشادات الطبيب تمامًا. سوف يقرر الطبيب المعالج التركيز المناسب لك من الأقراص حسب النظام العلاجي الحالي لديك وحالة المخاطر الشخصية لديك. ينبغي استشارة الطبيب أو الصيدلي في حالة عدم التأكد من كيفية الاستخدام.</p><p dir="RTL">قبل البدء في استخدام أتوزت؛ يجب أن تتّبع حميّة غذائيّة لخفض مستوى الكوليسترول لديك.</p><p dir="RTL">و عليك الإبقاء على الحمية الغذائيّة المُخفّضة للكولسترول وأنت تتناول أتوزت.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>مقدار الجرعة</u></p><p dir="RTL">الجرعة الموصى بها هي قرص واحد من أتوزت؛ يؤخذ عن طريق الفم مرة واحدة في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>موعد تناول الجرعة</u></p><p dir="RTL">يؤخذ أتوزت في أي وقت من اليوم. يمكن تناوله مع الطعام أو بدونه.</p><p dir="RTL">إذا وصف الطبيب لك أتوزت مع كوليسترامين أو أي عقار آخر عازل للحمض الصفراوي (أدوية مخفضة للكوليسترول)، ينبغي أخذ أتوزت قبل العقار العازل للحمض الصفراوي بساعتين على الأقل أو بعده بـ 4 ساعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة تناول جرعة زائدة من أتوزت </strong></p><p dir="RTL">يُرجى إخبار الطبيب أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة نسيان جرعة أتوزت</strong></p><p dir="RTL">لا تأخذ جرعة إضافية؛ وإنما خذ الجرعة العادية الموصوفة لك من أتوزت في موعدها المعتاد في اليوم التالي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أيّ أسئلة أخرى عن استخدام هذا الدواء، فاسأل الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">على غرار الأدوية كلّها، قد يُسبّب أتوزت أعراضًا جانبيّةً، وإن كان لا يُصاب الجميع بها.</p><p dir="RTL">إذا أُصبت بأيٍ من الأعراض الجانبية التالية او علامة مرض؛ يجب التوقف عن أخذ الأقراص وإخبار الطبيب فورًا أو الذهاب إلى قسم الطوارئ في أقرب مستشفى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية الخطيرة التي تؤدي الى تورم الوجه واللسان والحلق مما يسبب صعوبة بالغة في التنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض خطير مصحوب بتقشر شديد في الجلد وتورم،&nbsp; بثور بالجلد&nbsp; والفم والعينين والأعضاء التناسلية وحمى، طفح جلدي مع بقع حمراء وردية خصوصًا على كفيء اليدين أو باطن القدمين، وقد يصبهما بثور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف في العضلات أو حساسيّة عند اللمس ,ألم أو تمزق أو تغير البول الى اللون البني المحمر , أو ألم فيها خصوصًا عند الشعور بهما في وقت واحد؛ فإنك تشعر بتوعك أو ارتفاع درجة الحرارة؛ قد يكون ذلك بسبب انحلال عضلي غير طبيعي يمكن ان يهدد الحياة ويؤدي إلى مشاكل بالكُلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة مرض الذئبه مثل (بما في ذلك الطفح الجلدي, اضطرابات المفاصل والآثار علي خلايا الدم)</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي استشارة الطبيب في أسرع وقت ممكن عند حدوث مشكلات مصحوبة بنزيف غير متوقع أو غير عادي أو كدمات؛ لأن هذا قد يكون مؤشر بوجود &nbsp;مشكلة &nbsp;في الكبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وردت تقارير عن الأعراض الجانبية الشائعة التالية (يمكن أن تؤثر في شخص واحد من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في العضلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وردت تقارير عن الأعراض الجانبية غير الشائعة التالية (يمكن أن تؤثر في شخص واحد من كل 100 أشخاص):</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>أنفلونزا.</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>اكتئاب، أرق، اضطراب النوم،</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>دوار، صداع، إحساس بنخز</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>بطء نبض القلب</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>نوبات&nbsp;&nbsp; و هبات سخونة</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>قصر التنفس</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>ألم في البطن،&nbsp; الانتفاخ في البطن، إمساك، عسر هضم، انتفاخ، كثرة التبرز، التهاب المعدة، غثيان، توعك في المعدة، اضطراب المعدة</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>حب الشباب؛ شرى.</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>ألم في المفاصل، ألم في الظهر، تشنجات عضلية في الرجل، تعب عضلي أو تقلصات أو ضعف، ألم في الذراعين أو الرجلين.</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>ضعف غير عادي، شعور بالتعب أو التوعك، تورم خاصة في الكاحلين (وذمة).</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>ارتفاع في قيم نتائج بعض اختبارات الدم لوظائف الكبد أو العضلات.</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>زيادة الوزن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">علاوة على ذلك؛ وردت تقارير عن الأعراض الجانبية التالية في أشخاص يستخدمون أقراص أتوزت أو أقراص ايزيتيمايب أو أقراص أتورفاستاتين :</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية بما فيها تورم الوجه و/أو الشفتين واللسان والحلق، مما قد يؤدي إلى صعوبة أثناء التنفس أو البلع (تستدعي هذه الحالة العلاج الفوري).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاقم الطفح الجلدي مع الاحمرار؛ أحيانًا مع آفات على شكل مرمى السهم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سُعال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حرقة القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الشهية، فقدان الشهية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي وحكة، تفاعلات حساسية بما فيها طفح جلدي وشرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إصابة الأوتار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حصوات مراريّة أو التهاب المرارة (مما قد يسبب ألمًا في البطن، غثيان، قيء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس؛ يكون مصحوبًا بألم شديد في البطن غالبًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص عدد خلايا الدم مما قد يسبب كدمات أو نزيف (قلة الصفيحات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات الممرات الأنفية، نزيف الأنف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العنق، ألم، ألم في الصدر، ألم في الحلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع وانخفاض في مستويات سكر الدم (إذا كنت مصابًا بداء السُّكَري؛ فينبغي الاستمرار في المراقبة الدقيقة لمستويات سكر الدم لديك.)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الى رؤية أحلام مزعجة او كوابيس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تنمل أو خدر في أصابع اليدين وأصابع القدمين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الإحساس بالألم أو اللمس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في حاسة التذوق، جفاف الفم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الذاكرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طنين في الأذنين و/أو الرأس، فقدان السمع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجشؤ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سقوط الشعر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع درجة الحرارة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود كرات دم بيضاء في البول - حسب نتائج اختبارات البول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية ، اضطرابات في الرؤية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التثدي (تضخم الثديين لدى الرجال).</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأعراض &nbsp;الجانبية الممكنة التي تم الإبلاغ عنها مع بعض عقاقير الإستاتين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات جنسية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اكتئاب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات تنفسية بما فيها سعال مستمر و/أو قصر التنفس أو حمى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الداء السُّكَري. يزيد هذا الاحتمال إذا ارتفعت مستويات السُّكر والدهون في دمك وكنت بدينًا ومصابًا بضغط الدم المرتفع. سيقوم الطبيب بمراقبة حالتك أثناء استخدامك هذا الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم عضلي، أو&nbsp; حساسيّة عند اللمس أو ضعف عضلي مستمر؛ في الوقت نفسه تشعر بتوعك او تكون لديك حرارة عالية &nbsp;وفي حالات نادرة جدًا قد لا يزول بعد التوقف عن استخدام أتوزت.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الابلاغ عن الأعراض الجانبيّة المحتملة:</strong></p><p dir="RTL">اتّصل بالطبيب أو الصيدلي في حال تعرّضك لأي أعراض جانبيّة محتملة بالإضافة إلى تلك غير المذكورة في هذه النشرة. يمكنك الإبلاغ عن الأعراض الجانبيّة مباشرة من خلال &quot; المركز الوطني للتيقظ والسلامة الدوائية، التابع للهيئة العامة للغذاء والدواء &quot;</p><p dir="RTL">&nbsp;يُمكنك تأمين المزيد من المعلومات حول سلامة هذا الدواء من خلال الابلاغ عن الأعراض الجانبيّة.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><!--[if !supportLists]--></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ في درجة حرارة أقل من 30 درجة مئوية. .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ في العبوة الأصلية لحمايته من &nbsp;الاكسجين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ هذا الدواء بعيدًا عن متناول أيدي ومرأى الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يُستخدم أتوزت بعد تاريخ انتهاء الصلاحية المكتوب على كلٍ من العلبة الكرتونية أو الحاوية بعد الأحرف &quot;EXP&quot; (انتهاء الصلاحية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لا تحتاج إليها. ستساعد هذه التدابير على حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المواد الفعالة هي إزيتيميب وأتورفاستاتين. يحتوي كل قرص مغطى بطبقة رقيقة على 10 ملغم إزيتيميب و10 ملغم أو 20 ملغم أو 40 ملغم أتورفاستاتين (في صيغة أتورفاستاتين كالسيوم ثلاثي الهيدريت).</p><p dir="RTL">&nbsp;</p><p>المكونات الأخرى هي: كربونات كالسيوم، سيليكا غروانية لامائية، صوديوم كروسكارميلوز، هيدروكسي بروبيل سيلولوز، أحادي هيدريت اللاكتوز، ستيريت ماغنيسيوم، سيلولوز دقيق البلورات، بولي سوربيت 80، بوفيدون، لوريل سلفات صوديوم</p><p dir="RTL">تحتوي الطبقة الرقيقة المغلِّفة للقرص على:&nbsp; هايبروميلوز، ماكروجول 8000، ثاني أكسيد التيتانيوم (E171)، طلق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص على شكل كبسولات ومحدبة من الجانبين ومغلفة بطبقة رقيقة ولونها أبيض مائل إلى الأصفر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أقراص أتوزت 10 ملغم /10 ملغم: الرقم &quot;257&quot; منقوش على جانب واحد من القرص.</p><p dir="RTL">أقراص أتوزت 10 ملغم /20 ملغم: الرقم &quot;333&quot; منقوش على جانب واحد من القرص.</p><p dir="RTL">أقراص أتوزت 10 ملغم /40 ملغم: الرقم &quot;337&quot; منقوش على جانب واحد من القرص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أحجام العبوة:</strong></p><p dir="RTL">تتوفر عبوات بها 10 أقراص، 30 قرصًا، 90 قرصًا، و100 قرص مغلفة بطبقة رقيقة معبأة في شرائط ألومنيوم منفطة ( الأقراص معبأة في تجاويف الشريط المنفط بتقنية PA-Al-PVC، ومغطاة بغطاء رقيق من الألومنيوم).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتوفر عبوات فيها شريط واحد فيه 30 قرصًا، وشريط واحد فيه 45 قرصًا في جرعة وحداوية، وتكون الأقراص مغلفة بطبقة رقيقة ومعبأة في شرائط ألومنيوم منفطة معقمة بالنتروجين (الأقراص معبأة في تجاويف الشريط المنفط بتقنية PA-Al-PVC، ومغطاة بغطاء رقيق من الألومنيوم).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا يتم تسويق العبوات بكل الأحجام.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المالكة لحقوق التسويق :</strong></p><p dir="RTL">ميرك شارب آند دوهم المحدودة، طريق هيرتفورد ،</p><p dir="RTL">هوديسدون، هيرتفوردشاير، إي أن11 9بي يو،</p><p dir="RTL">المملكة المتحدة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة:</strong></p><p dir="RTL">أم أس دي انترناشونال المحدودة (فرع بورتو ريكو)&nbsp;</p><p dir="RTL">طريق ستيت 183، بريدكو اندستريال بارك،</p><p dir="RTL">لاس بيدراس، بورتو ريكو، 00771</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة بتاريخ مارس 2020





للإبلاغ عن الأعراض الجانبية:
•	المملكة العربية السعودية:
المركز الوطني للتيقظ والسلامة الدوائية
للاتصال باالهيئة العامة للغذاء والدواء: 1999
البريد الالكتروني: npc.drug@sfda.gov.sa
الموقع الالكتروني: https://ade.sfda.gov.sa

•	دول الخليج الأخرى
الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل دولة.











( إنَّ هذا الدواء)
- الدواء مستحضر يؤثر على صحتك واستهلاكه خلافًا للتعليمات يعرضك للخطر
- اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلاني الذي صرفها لك
- إن الطبيب و الصيدلي هما الخبيران بالدواء وبنفعه وضرره
- لا تقطع مدة العلاج المحددة لك من تلقاء نفسك
- لا تكرر صرف الدواء بدون استشارة الطبيب
- لا تترك الأدوية في متناول أيدي الأطفال

مجلس وزراء الصحة العرب
و اتحاد الصيادلة العرب
تمت الموافقة على نشرة المعلومات الخاصة بالمريض من قبل الهيئة العامة للغذاء والدواء بالمملكة العربية السعودية

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ATOZET® 10 mg/10 mg film-coated tablets 
ATOZET® 10 mg/20 mg film-coated tablets 
ATOZET® 10 mg/40 mg film-coated tablets 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 10 mg of ezetimibe and 10, 20 or 40 mg of atorvastatin (as atorvastatin calcium trihydrate).

Excipient(s) with known effect
Each 10 mg/10 mg film-coated tablet contains 153 mg of lactose. Each 10 mg/20 mg film-coated tablet contains 179 mg of lactose. Each 10 mg/40 mg film-coated tablet contains 230 mg of lactose. 

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet

10 mg/10 mg tablet: Capsule-shaped, biconvex, white to off-white, film-coated, size 12.74 mm x
5.10 mm, “257” debossed on one side
10 mg/20 mg tablet: Capsule-shaped, biconvex, white to off-white, film-coated, size 14.48 mm x
5.79 mm, “333” debossed on one side
10 mg/40 mg tablet: Capsule-shaped, biconvex, white to off-white, film-coated size 16.38 mm x
6.27 mm, “337” debossed on one side

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Prevention of Cardiovascular Events</u></em></p><p>ATOZET is indicated to reduce the risk of cardiovascular events (see section 5.1) in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS), either previously treated with a statin or not.</p><p>&nbsp;</p><p><em>Hypercholesterolaemia</em></p><p>ATOZET is indicated as adjunctive therapy to diet for use in adults with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patients not appropriately controlled with a statin alone</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patients already treated with a statin and ezetimibe</p><p>&nbsp;</p><p><em>Homozygous Familial Hypercholesterolaemia (HoFH)</em></p><p>ATOZET is indicated as adjunctive therapy to diet for use in adults with HoFH. Patients may also receive adjunctive treatments (e.g., low-density lipoprotein [LDL] apheresis).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p><u>Posology</u></p><p>&nbsp;</p><p><em>Hypercholesterolaemia and/or Coronary Heart Disease (with ACS History)</em></p><p>The patient should be on an appropriate lipid-lowering diet and should continue on this diet during treatment with ATOZET.</p><p>&nbsp;</p><p>The dose range of ATOZET is 10/10 mg/day through 10/80 mg/day. The typical dose is 10/10 mg once a day. The patient&rsquo;s low-density lipoprotein cholesterol (LDL-C) level, coronary heart disease risk status, and response to current cholesterol-lowering therapy should be considered when starting therapy or adjusting the dose.</p><p>&nbsp;</p><p>The dose of ATOZET should be individualised based on the known efficacy of the various dose strengths of ATOZET (see section 5.1, Table 4) and the response to the current cholesterol-lowering therapy.</p><p>Adjustment of dose should be made at intervals of 4 weeks or more.</p><p>&nbsp;</p><p><em>Homozygous Familial Hypercholesterolaemia</em></p><p>The dose of ATOZET in patients with homozygous FH is 10/10 to 10/80 mg daily. ATOZET may be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable.</p><p>&nbsp;</p><p><em>Co-administration with other medicines</em></p><p>Dosing of ATOZET should occur either &sup3;2 hours before or &sup3;4 hours after administration of a bile acid sequestrant.</p><p>&nbsp;</p><p>In patients taking hepatitis C antiviral agents elbasvir/grazoprevir concomitantly with ATOZET, the dose of ATOZET should not exceed 10/20 mg/day (see sections 4.4 and 4.5).</p><p>&nbsp;</p><p><em>Elderly</em></p><p>No dose adjustment is required for older patients (see section 5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of ATOZET in children has not been established (see section 5.2). No data are available.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>ATOZET should be used with caution in patients with hepatic impairment (see sections 4.4 and 5.2). ATOZET is contraindicated in patients with active liver disease (see section 4.3).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment is required for renally impaired patients (see section 5.2).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>ATOZET is for oral administration. ATOZET can be administered as a single dose at any time of the day, with or without food.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

Therapy with ATOZET is contraindicated during pregnancy and breast-feeding, and in women of child- bearing potential not using appropriate contraceptive measures (see section 4.6).

ATOZET is contraindicated in patients with active liver disease or unexplained persistent elevations in serum transaminases exceeding 3 times the upper limit of normal (ULN).

ATOZET is contraindicated in patients treated with the hepatitis C antivirals glecaprevir/pibrentasvir.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Myopathy/Rhabdomyolysis</u></p><p>In post-marketing experience with ezetimibe, cases of myopathy and rhabdomyolysis have been reported. Most patients who developed rhabdomyolysis were taking a statin concomitantly with ezetimibe.</p><p>However, rhabdomyolysis has been reported very rarely with ezetimibe monotherapy and very rarely with the addition of ezetimibe to other agents known to be associated with increased risk of rhabdomyolysis.</p><p>&nbsp;</p><p>ATOZET contains atorvastatin. Atorvastatin, like other HMG-CoA reductase inhibitors, may in rare occasions affect the skeletal muscle and cause myalgia, myositis, and myopathy that may progress to rhabdomyolysis, a potentially life-threatening condition characterised by markedly elevated creatine phosphokinase (CPK) levels (&gt;10 times ULN), myoglobinaemia and myoglobinuria, which may lead to renal failure.</p><p>&nbsp;</p><p><em>Before the treatment</em></p><p>ATOZET should be prescribed with caution in patients with pre-disposing factors for rhabdomyolysis. A CPK level should be measured before starting treatment in the following situations:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; renal impairment,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypothyroidism,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; personal or familial history of hereditary muscular disorders,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; previous history of muscular toxicity with a statin or fibrate,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; previous history of liver disease and/or where substantial quantities of alcohol are consumed,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in elderly (age &gt;70 years), the necessity of such measurement should be considered, according to the presence of other predisposing factors for rhabdomyolysis,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; situations where an increase in plasma levels may occur, such as interactions (see section 4.5) and special populations including genetic subpopulations (see section 5.2).</p><p>&nbsp;</p><p>In such situations, the risk of treatment should be considered in relation to possible benefit, and clinical monitoring is recommended.</p><p>&nbsp;</p><p>If CPK levels are significantly elevated (&gt;5 times ULN) at baseline, treatment should not be started.</p><p>&nbsp;</p><p><em>Creatine phosphokinase measurement</em></p><p>&nbsp;</p><p>Creatine phosphokinase (CPK) should not be measured following strenuous exercise or in the presence of any plausible alternative cause of CPK increase as this makes value interpretation difficult. If CPK levels are significantly elevated at baseline (&gt;5 times ULN), levels should be remeasured within 5 to 7 days later to confirm the results.</p><p>&nbsp;</p><p><em>Whilst on treatment</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients must be asked to promptly report muscle pain, cramps, or weakness especially if accompanied by malaise or fever or if muscle signs and symptoms persist after discontinuing ATOZET.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If such symptoms occur whilst a patient is receiving treatment with ATOZET, their CPK levels should be measured. If these levels are found to be significantly elevated (&gt;5 times ULN), treatment should be stopped.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If muscular symptoms are severe and cause daily discomfort, even if the CPK levels are elevated to &le;5 times ULN, treatment discontinuation should be considered.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If symptoms resolve and CPK levels return to normal, then re-introduction of ATOZET or introduction of another statin-containing product may be considered at the lowest dose and with close monitoring.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ATOZET must be discontinued if clinically significant elevation of CPK levels (&gt;10 times ULN) occur, or if rhabdomyolysis is diagnosed or suspected.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There have been very rare reports of an immune-mediated necrotising myopathy (IMNM) during or after treatment with some statins. IMNM is clinically characterised by persistent proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment.</p><p>&nbsp;</p><p>Due to the atorvastatin component of ATOZET, the risk of rhabdomyolysis is increased when ATOZET is administered concomitantly with certain medicinal products that may increase the plasma concentration of atorvastatin such as potent inhibitors of CYP3A4 or transport proteins (e.g., ciclosporin, telithromycin, clarithromycin, delavirdine, stiripentol, ketoconazole, voriconazole, itraconazole, posaconazole, and HIV protease inhibitors including ritonavir, lopinavir, atazanavir, indinavir, darunavir, tipranavir/ritonavir, etc). The risk of myopathy may also be increased with the concomitant use of gemfibrozil and other fibric acid derivatives, antivirals for the treatment of hepatitis C (HCV) (boceprevir, telaprevir, elbasvir/grazoprevir), erythromycin, or niacin. If possible, alternative (non-interacting) therapies should be considered instead of these medicinal products (see section 4.8).</p><p>&nbsp;</p><p>In cases where co-administration of these medicinal products with ATOZET is necessary, the benefit and the risk of concurrent treatment should be carefully considered. When patients are receiving medicinal products that increase the plasma concentration of atorvastatin, a lower maximum dose of ATOZET is recommended. In addition, in the case of potent CYP3A4 inhibitors, a lower starting dose of ATOZET should be considered and appropriate clinical monitoring of these patients is recommended (see section 4.5).</p><p>&nbsp;</p><p>Atorvastatin must not be co-administered with systemic formulations of fusidic acid or within 7 days of stopping fusidic acid treatment. In patients where the use of systemic fusidic acid is considered essential, statin treatment should be discontinued throughout the duration of fusidic acid treatment. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving fusidic acid and statins in combination (see section 4.5). The patient should be advised to seek medical advice immediately if they experience any symptoms of muscle weakness, pain or tenderness.</p><p>&nbsp;</p><p>Statin therapy may be re-introduced seven days after the last dose of fusidic acid.</p><p>&nbsp;</p><p>In exceptional circumstances, where prolonged systemic fusidic acid is needed, e.g., for the treatment of severe infections, the need for co-administration of ATOZET and fusidic acid should only be considered on a case by case basis and under close medical supervision.</p><p>&nbsp;</p><p><u>Daptomycin</u></p><p>Cases of myopathy and/or rhabdomyolysis have been reported with HMG-CoA reductase inhibitors (e.g. atorvastatin and ezetimibe/atorvastatin) co-administered with daptomycin. Caution should be used when prescribing HMG-CoA reductase inhibitors with daptomycin, as either agent can cause myopathy and/or rhabdomyolysis when given alone. Consideration should be given to temporarily suspend ATOZET in patients taking daptomycin unless the benefits of concomitant administration outweigh the risk. Consult the prescribing information of Daptomycin to obtain further information about this potential interaction with HMG-CoA reductase inhibitors (e.g. atorvastatin and ezetimibe/atorvastatin) and for further guidance related to monitoring (see section 4.5.).</p><p>&nbsp;</p><p><u>Liver Enzymes</u></p><p>In controlled co-administration trials in patients receiving ezetimibe and atorvastatin, consecutive transaminase elevations (&ge;3 times the upper limit of normal [ULN]) have been observed (see section 4.8.).</p><p>&nbsp;</p><p>Liver function tests should be performed before the initiation of treatment and periodically thereafter. Patients who develop any signs or symptoms suggestive of liver injury should have liver function tests performed. Patients who develop increased transaminase levels should be monitored until the abnormality(ies) resolve. Should an increase in transaminases of greater than 3 times the ULN persist, reduction of dose or withdrawal of ATOZET is recommended.</p><p>&nbsp;</p><p>ATOZET should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of liver disease.</p><p>&nbsp;</p><p><u>Hepatic Insufficiency</u></p><p>Due to the unknown effects of the increased exposure to ezetimibe in patients with moderate or severe hepatic insufficiency, ATOZET is not recommended (see section 5.2).</p><p>&nbsp;</p><p><u>Fibrates</u></p><p>The safety and efficacy of ezetimibe administered with fibrates have not been established; therefore, co- administration of ATOZET and fibrates is not recommended (see section 4.5).</p><p>&nbsp;</p><p><u>Ciclosporin</u></p><p>Caution should be exercised when initiating ATOZET in the setting of ciclosporin. Ciclosporin concentrations should be monitored in patients receiving ATOZET and ciclosporin (see section 4.5).</p><p>&nbsp;</p><p><u>Anticoagulants</u></p><p>If ATOZET is added to warfarin, another coumarin anticoagulant, or fluindione, the International Normalised Ratio (INR) should be appropriately monitored (see section 4.5).</p><p>&nbsp;</p><p><u>Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL)</u></p><p>In a post-hoc analysis of stroke subtypes in patients without coronary heart disease (CHD) who had a recent stroke or transient ischaemic attack (TIA) there was a higher incidence of haemorrhagic stroke in patients initiated on atorvastatin 80 mg compared to placebo. The increased risk was particularly noted in patients with prior haemorrhagic stroke or lacunar infarct at study entry. For patients with prior haemorrhagic stroke or lacunar infarct, the balance of risks and benefits of atorvastatin 80 mg is</p><p>&nbsp;</p><p>uncertain, and the potential risk of haemorrhagic stroke should be carefully considered before initiating treatment (see section 5.1).</p><p>&nbsp;</p><p><u>Interstitial lung disease</u></p><p>Exceptional cases of interstitial lung disease have been reported with some statins, especially with long term therapy (see section 4.8). Presenting features can include dyspnoea, non-productive cough and deterioration in general health (fatigue, weight loss and fever). If it is suspected a patient has developed interstitial lung disease, statin therapy should be discontinued.</p><p>&nbsp;</p><p><u>Diabetes mellitus</u></p><p>Some evidence suggests that statins as a class raise blood glucose and in some patients, at high risk of future diabetes, may produce a level of hyperglycaemia where formal diabetes care is appropriate. This risk, however, is outweighed by the reduction in vascular risk with statins and therefore should not be a reason for stopping statin treatment. Patients at risk (fasting glucose 5.6 to 6.9 mmol/L, BMI&gt;30kg/m2, raised triglycerides, hypertension) should be monitored both clinically and biochemically according to national guidelines.</p><p>&nbsp;</p><p><u>Excipients</u></p><p>ATOZET contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine.</p><p>&nbsp;</p><p>ATOZET contains less than 1 mmol (23 mg) sodium per tablet and is considered to be essentially sodium-free</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>Multiple mechanisms may contribute to potential interactions with HMG Co-A reductase inhibitors. Drugs or herbal products that inhibit certain enzymes (e.g. CYP3A4) and/or transporter (e.g., OATP1B) pathways may increase atorvastatin plasma concentrations and may lead to an increased risk of myopathy/rhabdomyolysis.</p><p>&nbsp;</p><p>Consult the prescribing information of all concomitantly used drugs to obtain further information about their potential interactions with atorvastatin and/or the potential for enzyme or transporter alterations and possible adjustments to dose and regimens.</p><p><strong>&nbsp;</strong></p><p><u>Pharmacodynamic interactions</u></p><p>Atorvastatin is metabolised by cytochrome P450 3A4 (CYP3A4) and is a substrate of the hepatic transporters, organic anion-transporting polypeptide 1B1 (OATP1B1) and 1B3 (OATP1B3) transporter. Metabolites of atorvastatin are substrates of OATP1B1. Atorvastatin is also identified as a substrate of the multi-drug resistance protein 1 (MDR1) and breast cancer resistance protein (BCRP), which may limit the intestinal absorption and biliary clearance of atorvastatin (see section 5.2). Concomitant administration of medicinal products that are inhibitors of CYP3A4 or transport proteins may lead to increased plasma concentrations of atorvastatin and an increased risk of myopathy. The risk might also be increased at concomitant administration of ATOZET with other medicinal products that have a potential to induce myopathy, such as fibric acid derivatives and ezetimibe (see section 4.4).</p><p>&nbsp;</p><p><u>Pharmacokinetic interactions</u></p><p><em>ATOZET</em></p><p>No clinically significant pharmacokinetic interaction was seen when ezetimibe was co-administered with atorvastatin.</p><p>&nbsp;</p><p><em>Effects of other medicinal products on ATOZET Ezetimibe</em></p><p>&nbsp;</p><p><em>Antacids: </em>Concomitant antacid administration decreased the rate of absorption of ezetimibe but had no effect on the bioavailability of ezetimibe. This decreased rate of absorption is not considered clinically significant.</p><p>&nbsp;</p><p><em>Cholestyramine: </em>Concomitant cholestyramine administration decreased the mean area under the curve (AUC) of total ezetimibe (ezetimibe + ezetimibe glucuronide) approximately 55%. The incremental</p><p>low-density lipoprotein cholesterol (LDL-C) reduction due to adding ATOZET to cholestyramine may be lessened by this interaction (see section 4.2).</p><p>&nbsp;</p><p><em>Ciclosporin: </em>In a study of eight post-renal transplant patients with creatinine clearance of &gt;50 mL/min on a stable dose of ciclosporin, a single 10-mg dose of ezetimibe resulted in a 3.4-fold (range 2.3- to</p><p>7.9-fold) increase in the mean AUC for total ezetimibe compared to a healthy control population, receiving ezetimibe alone, from another study (n=17). In a different study, a renal transplant patient with severe renal insufficiency who was receiving ciclosporin and multiple other medicinal products demonstrated a 12-fold greater exposure to total ezetimibe compared to concurrent controls receiving ezetimibe alone. In a two-period crossover study in twelve healthy subjects, daily administration of 20 mg ezetimibe for 8 days with a single 100-mg dose of ciclosporin on Day 7 resulted in a mean 15% increase in ciclosporin AUC (range 10% decrease to 51% increase) compared to a single 100-mg dose of ciclosporin alone. A controlled study on the effect of co-administered ezetimibe on ciclosporin exposure in renal transplant patients has not been conducted. Caution should be exercised when initiating ATOZET in the setting of ciclosporin. Ciclosporin concentrations should be monitored in patients receiving ATOZET and ciclosporin (see section 4.4).</p><p>&nbsp;</p><p><em>Fibrates: </em>Concomitant fenofibrate or gemfibrozil administration increased total ezetimibe concentrations approximately 1.5- and 1.7-fold, respectively. Although these increases are not considered clinically significant, co-administration of ATOZET with fibrates is not recommended (see section 4.4).</p><p>&nbsp;</p><p><em>Atorvastatin</em></p><p><em>&nbsp;</em></p><p><em>CYP3A4 inhibitors: </em>Potent CYP3A4 inhibitors have been shown to lead to markedly increased concentrations of atorvastatin (see Table 1 and specific information below). Co-administration of potent CYP3A4 inhibitors (e.g., ciclosporin, telithromycin, clarithromycin, delavirdine, stiripentol, ketoconazole, voriconazole, itraconazole, posaconazole, some antivirals used in the treatment of HCV (e.g., elbasvir/grazoprevir) and HIV protease inhibitors including ritonavir, lopinavir, atazanavir, indinavir, darunavir, etc.) should be avoided if possible. In cases where co-administration of these medicinal products with ATOZET cannot be avoided, lower starting and maximum doses of ATOZET should be considered and appropriate clinical monitoring of the patient is recommended (see Table 1).</p><p>&nbsp;</p><p>Moderate CYP3A4 inhibitors (e.g., erythromycin, diltiazem, verapamil and fluconazole) may increase plasma concentrations of atorvastatin (see Table 1). An increased risk of myopathy has been observed with the use of erythromycin in combination with statins. Interaction studies evaluating the effects of amiodarone or verapamil on atorvastatin have not been conducted. Both amiodarone and verapamil are known to inhibit CYP3A4 activity and co-administration with ATOZET may result in increased exposure to atorvastatin. Therefore, a lower maximum dose of ATOZET should be considered and appropriate clinical monitoring of the patient is recommended when concomitantly used with moderate CYP3A4 inhibitors. Appropriate clinical monitoring is recommended after initiation or following dose adjustments of the inhibitor.</p><p>&nbsp;</p><p><em>Inhibitors of Breast Cancer Resistant Protein (BCRP): </em>Concomitant administration of products that are inhibitors of BCRP (e.g., elbasvir and grazoprevir) may lead to increased plasma concentrations of</p><p>&nbsp;</p><p>atorvastatin and an increased risk of myopathy; therefore, a dose adjustment of atorvastatin should be considered depending on the prescribed dose. Co-administration of elbasvir and grazoprevir with atorvastatin increases plasma concentrations of atorvastatin 1.9-fold (see Table 1); therefore, the dose of ATOZET should not exceed 10/20 mg daily in patients receiving concomitant medications with products containing elbasvir or grazoprevir (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p><em>Inducers of cytochrome P450 3A4: </em>Concomitant administration of atorvastatin with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampicin, St. John&#39;s Wort) can lead to variable reductions in plasma concentrations of atorvastatin. Due to the dual interaction mechanism of rifampicin, (cytochrome P450 3A4 induction and inhibition of hepatocyte uptake transporter OATP1B1), simultaneous co- administration of ATOZET with rifampicin is recommended, as delayed administration of atorvastatin after administration of rifampicin has been associated with a significant reduction in atorvastatin plasma concentrations. The effect of rifampicin on atorvastatin concentrations in hepatocytes is, however, unknown and if concomitant administration cannot be avoided, patients should be carefully monitored for efficacy.</p><p>&nbsp;</p><p><em>Transport&nbsp; inhibitors: </em>Inhibitors of transport proteins (e.g., ciclosporin) can increase the systemic exposure of atorvastatin (see Table 1). The effect of inhibition of hepatic uptake transporters on atorvastatin concentrations in hepatocytes is unknown. If concomitant administration cannot be avoided, a dose reduction of ATOZET and clinical monitoring for efficacy is recommended (see Table 1).</p><p>&nbsp;</p><p><em>Gemfibrozil / fibric acid derivatives: </em>The use of fibrates alone is occasionally associated with muscle- related events, including rhabdomyolysis. The risk of these events may be increased with the concomitant use of fibric acid derivatives and atorvastatin.</p><p>&nbsp;</p><p><em>Ezetimibe: </em>The use of ezetimibe alone is associated with muscle-related events, including rhabdomyolysis. The risk of these events may therefore be increased with concomitant use of ezetimibe and atorvastatin. Appropriate clinical monitoring of these patients is recommended.</p><p>&nbsp;</p><p><em>Colestipol: </em>Plasma concentrations of atorvastatin and its active metabolites were lower (by approx. 25%) when colestipol was co-administered with atorvastatin. However, lipid effects were greater when atorvastatin and colestipol were co-administered than when either medicinal product was given alone.</p><p>&nbsp;</p><p><em>Fusidic acid: </em>The risk of myopathy including rhabdomyolysis may be increased by the concomitant administration of systemic fusidic acid with statins. The mechanism of this interaction (whether it is pharmacodynamic or pharmacokinetic, or both) is yet unknown. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving this combination.</p><p>&nbsp;</p><p>If treatment with systemic fusidic acid is necessary, atorvastatin treatment should be discontinued throughout the duration of the fusidic acid treatment. <strong>Also see section 4.4.</strong></p><p><strong>&nbsp;</strong></p><p><em>Colchicine: </em>Although interaction studies with atorvastatin and colchicine have not been conducted, cases of myopathy have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine.</p><p>&nbsp;</p><p><em>Daptomycin: </em>The risk of myopathy and/or rhabdomyolysis may be increased by concomitant administration of HMG-CoA reductase inhibitors and daptomycin. Consideration should be given to suspending ATOZET temporarily in patients taking daptomycin unless the benefits of concomitant administration outweigh the risk (see section 4.4).</p><p>&nbsp;</p><p><em>Boceprevir: </em>Exposure to atorvastatin was increased when administered with boceprevir. When co- administration with ATOZET is required, starting with the lowest possible dose of ATOZET should be considered with titration up to desired clinical effect while monitoring for safety, without exceeding a daily dose of 10/20 mg. For patients currently taking ATOZET, the dose of ATOZET should not exceed a daily dose of 10/20 mg during co-administration with boceprevir.</p><p>&nbsp;</p><p><em>Effects of ATOZET on the pharmacokinetics of other medicinal products Ezetimibe</em></p><p>In preclinical studies, it has been shown that ezetimibe does not induce cytochrome P450 drug metabolising enzymes. No clinically significant pharmacokinetic interactions have been observed between ezetimibe and drugs known to be metabolised by cytochromes P450 1A2, 2D6, 2C8, 2C9, and 3A4, or N-acetyltransferase.</p><p>&nbsp;</p><p><em>Anticoagulants: </em>Concomitant administration of ezetimibe (10 mg once daily) had no significant effect on bioavailability of warfarin and prothrombin time in a study of twelve healthy adult males. However, there have been post-marketing reports of increased International Normalised Ratio (INR) in patients who had ezetimibe added to warfarin or fluindione. If ATOZET is added to warfarin, another coumarin anticoagulant, or fluindione, INR should be appropriately monitored (see section 4.4).</p><p>&nbsp;</p><p><em>Atorvastatin</em></p><p><em>&nbsp;</em></p><p><em>Digoxin: </em>When multiple doses of digoxin and 10 mg atorvastatin were co-administered, steady-state digoxin concentrations increased slightly. Patients taking digoxin should be monitored appropriately.</p><p>&nbsp;</p><p><em>Oral contraceptives: </em>Co-administration of atorvastatin with an oral contraceptive produced increases in plasma concentrations of norethisterone and ethinyl estradiol.</p><p>&nbsp;</p><p><em>Warfarin: </em>In a clinical study in patients receiving chronic warfarin therapy, co-administration of atorvastatin 80 mg daily with warfarin caused a small decrease of about 1.7 seconds in prothrombin time during the first 4 days of dosing, which returned to normal within 15 days of atorvastatin treatment.</p><p>Although only very rare cases of clinically significant anticoagulant interactions have been reported, prothrombin time should be determined before starting ATOZET in patients taking coumarin anticoagulants and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs. Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants. If the dose of ATOZET is changed or discontinued, the same procedure should be repeated. Atorvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.</p><p>&nbsp;</p><p>Table 1</p><p><strong>Effect of Co-administered Medicinal Products on the Pharmacokinetics of Atorvastatin</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Co-administered Medicinal Product and Dosing Regimen</p></td><td colspan="2" style="vertical-align:top"><p>Atorvastatin</p></td><td style="vertical-align:top"><p>ATOZET</p></td></tr><tr><td style="vertical-align:top"><p>Dose (mg)</p></td><td style="vertical-align:top"><p>Change in AUC<sup>&amp;</sup></p></td><td style="vertical-align:top"><p>Clinical Recommendation<sup>#</sup></p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Tipranavir 500 mg BID/ Ritonavir 200 mg BID, 8 days (Days 14 to 21)</p></td><td style="vertical-align:top"><p>40 mg on Day 1,</p><p>10 mg on Day 20</p></td><td style="vertical-align:top"><p>&uarr; 9.4 fold</p></td><td rowspan="2" style="vertical-align:top"><p>In cases where co- administration with ATOZET is necessary, do not exceed 10/10 mg ATOZET daily.</p><p>Clinical monitoring of these patients is recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Ciclosporin 5.2 mg/kg/day, stable dose</p></td><td style="vertical-align:top"><p>10 mg OD for 28 days</p></td><td style="vertical-align:top"><p>&uarr; 8.7 fold</p></td></tr><tr><td style="vertical-align:top"><p>Lopinavir 400 mg BID/ Ritonavir 100 mg BID, 14 days</p></td><td style="vertical-align:top"><p>20 mg OD for 4 days</p></td><td style="vertical-align:top"><p>&uarr; 5.9 fold</p></td><td rowspan="2" style="vertical-align:top"><p>In cases where co- administration with ATOZET is necessary, lower maintenance doses of ATOZET are recommended. At ATOZET doses exceeding 10/20 mg, clinical monitoring of these patients is recommended<em>.</em></p></td></tr><tr><td style="vertical-align:top"><p>Clarithromycin 500 mg BID, 9 days</p></td><td style="vertical-align:top"><p>80 mg OD for 8 days</p></td><td style="vertical-align:top"><p>&uarr; 4.4 fold</p></td></tr><tr><td style="vertical-align:top"><p>Saquinavir 400 mg BID/ Ritonavir 300 mg BID from Days 5-7, increased to 400 mg BID on Day 8), Days 5-18, 30 min after atorvastatin dosing</p></td><td style="vertical-align:top"><p>40 mg OD for 4 days</p></td><td style="vertical-align:top"><p>&uarr; 3.9 fold</p></td><td rowspan="5" style="vertical-align:top"><p>In cases where co- administration with ATOZET is necessary, lower maintenance doses of ATOZET are recommended. At ATOZET doses exceeding 10/40 mg, clinical monitoring of these patients is recommended<em>.</em></p></td></tr><tr><td style="vertical-align:top"><p>Darunavir 300 mg BID/ Ritonavir 100 mg BID, 9 days</p></td><td style="vertical-align:top"><p>10 mg OD for 4 days</p></td><td style="vertical-align:top"><p>&uarr; 3.3 fold</p></td></tr><tr><td style="vertical-align:top"><p>Itraconazole 200 mg OD, 4 days</p></td><td style="vertical-align:top"><p>40 mg SD</p></td><td style="vertical-align:top"><p>&uarr; 3.3 fold</p></td></tr><tr><td style="vertical-align:top"><p>Fosamprenavir 700 mg BID/ Ritonavir 100 mg BID, 14 days</p></td><td style="vertical-align:top"><p>10 mg OD for 4 days</p></td><td style="vertical-align:top"><p>&uarr; 2.5 fold</p></td></tr><tr><td style="vertical-align:top"><p>Fosamprenavir 1400 mg BID, 14 days</p></td><td style="vertical-align:top"><p>10 mg OD for 4 days</p></td><td style="vertical-align:top"><p>&uarr; 2.3 fold</p></td></tr><tr><td style="vertical-align:top"><p>Nelfinavir 1250 mg BID, 14 days</p></td><td style="vertical-align:top"><p>10 mg OD for 28 days</p></td><td style="vertical-align:top"><p>&uarr; 1.7 fold^</p></td><td style="vertical-align:top"><p>No specific recommendation.</p></td></tr><tr><td style="vertical-align:top"><p>Grapefruit juice, 240 mL OD*</p></td><td style="vertical-align:top"><p>40 mg SD</p></td><td style="vertical-align:top"><p>&uarr; 37%</p></td><td style="vertical-align:top"><p>Concomitant intake of large quantities of grapefruit juice and ATOZET is not</p><p>recommended.</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Diltiazem 240 mg OD, 28 days</p></td><td style="vertical-align:top"><p>40 mg SD</p></td><td style="vertical-align:top"><p>&uarr; 51%</p></td><td style="vertical-align:top"><p>After initiation or following dose adjustments of diltiazem, appropriate clinical monitoring of these patients is</p><p>recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Erythromycin 500 mg QID, 7 days</p></td><td style="vertical-align:top"><p>10 mg SD</p></td><td style="vertical-align:top"><p>&uarr; 33%^</p></td><td style="vertical-align:top"><p>Lower maximum dose and clinical monitoring of these patients is</p><p>recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Amlodipine 10 mg, single dose</p></td><td style="vertical-align:top"><p>80 mg SD</p></td><td style="vertical-align:top"><p>&uarr; 18%</p></td><td style="vertical-align:top"><p>No specific</p><p>recommendation.</p></td></tr><tr><td style="vertical-align:top"><p>Cimetidine 300 mg QID, 2 weeks</p></td><td style="vertical-align:top"><p>10 mg OD for 4 weeks</p></td><td style="vertical-align:top"><p>&darr; less than 1%^</p></td><td style="vertical-align:top"><p>No specific recommendation.</p></td></tr><tr><td style="vertical-align:top"><p>Antacid suspension of magnesium and aluminium hydroxides, 30 mL QID,</p><p>2 weeks</p></td><td style="vertical-align:top"><p>10 mg OD for 4 weeks</p></td><td style="vertical-align:top"><p>&darr; 35%^</p></td><td style="vertical-align:top"><p>No specific recommendation.</p></td></tr><tr><td style="vertical-align:top"><p>Efavirenz 600 mg OD, 14 days</p></td><td style="vertical-align:top"><p>10 mg for 3 days</p></td><td style="vertical-align:top"><p>&darr; 41%</p></td><td style="vertical-align:top"><p>No specific</p><p>recommendation.</p></td></tr><tr><td style="vertical-align:top"><p>Rifampicin 600 mg OD, 7 days (co- administered)</p></td><td style="vertical-align:top"><p>40 mg SD</p></td><td style="vertical-align:top"><p>&uarr; 30%</p></td><td rowspan="2" style="vertical-align:top"><p>If co-administration cannot be avoided, simultaneous co- administration of ATOZET with rifampicin is</p><p>recommended, with clinical monitoring.</p></td></tr><tr><td style="vertical-align:top"><p>Rifampicin 600 mg OD, 5 days (doses separated)</p></td><td style="vertical-align:top"><p>40 mg SD</p></td><td style="vertical-align:top"><p>&darr; 80%</p></td></tr><tr><td style="vertical-align:top"><p>Gemfibrozil 600 mg BID, 7 days</p></td><td style="vertical-align:top"><p>40 mg SD</p></td><td style="vertical-align:top"><p>&uarr; 35%</p></td><td style="vertical-align:top"><p>Not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Fenofibrate 160 mg OD, 7 days</p></td><td style="vertical-align:top"><p>40 mg SD</p></td><td style="vertical-align:top"><p>&uarr; 3%</p></td><td style="vertical-align:top"><p>Not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Boceprevir 800 mg TID, 7 days</p></td><td style="vertical-align:top"><p>40 mg SD</p></td><td style="vertical-align:top"><p>&uarr; 2.3 fold</p></td><td style="vertical-align:top"><p>Lower starting dose and clinical monitoring of these patients is recommended. The dose of ATOZET should not exceed a daily dose of 10/20 mg during co- administration with</p><p>boceprevir.</p></td></tr><tr><td style="vertical-align:top"><p>Elbasvir 50 mg OD/Grazoprevir 200 mg OD, 13 days</p></td><td style="vertical-align:top"><p>10 mg SD</p></td><td style="vertical-align:top"><p>&uarr;1.94 fold</p></td><td style="vertical-align:top"><p>The dose of ATOZET should not exceed a daily dose of 10/20 mg</p><p>during co-</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>administration with products containing elbasvir or grazoprevir.</p></td></tr><tr><td style="vertical-align:top"><p>Glecaprevir 400 mg OD/Pibrentasvir 120 mg OD, 7 days</p></td><td style="vertical-align:top"><p>10 mg OD for 7 days</p></td><td style="vertical-align:top"><p>&uarr; 8.3 fold</p></td><td style="vertical-align:top"><p>Co-administration with products containing glecaprevir or pibrentasvir is contraindicated (see</p><p>section 4.3).</p></td></tr></tbody></table><p>&amp; Data given as x-fold change represent a simple ratio between co-administration and atorvastatin alone (i.e., 1-fold = no change). Data given as % change represent % difference relative to atorvastatin alone (i.e., 0% = no change).</p><p>#&nbsp;&nbsp;&nbsp; See sections 4.4 and 4.5 for clinical significance.</p><p>*&nbsp;&nbsp;&nbsp; Contains one or more components that inhibit CYP3A4 and can increase plasma concentrations of medicinal products metabolised by CYP3A4. Intake of one 240 mL glass of grapefruit juice also resulted in a decreased AUC of 20.4% for the active orthohydroxy metabolite. Large quantities of grapefruit juice (over 1.2 l daily for 5 days) increased AUC of atorvastatin 2.5 fold and AUC of active (atorvastatin and metabolites).</p><p>^&nbsp;&nbsp;&nbsp; Total atorvastatin equivalent activity Increase is indicated as &ldquo;&uarr;&rdquo;, decrease as &ldquo;&darr;&rdquo;</p><p>OD = once daily; SD = single dose; BID = twice daily; TID = three times daily; QID = four times daily</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Table 2</p><p><strong>Effect of Atorvastatin on the Pharmacokinetics of Co-administered Medicinal Products</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p>Atorvastatin and Dosing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Co-administered Medicinal Product&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ATOZET Regimen Medicinal Product/Dose&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change in AUC<sup>&amp;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical</p><p>(mg)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommendation</p></td></tr><tr><td style="vertical-align:top"><p>80 mg OD for 10 days</p></td><td style="vertical-align:top"><p>Digoxin 0.25 mg OD, 20 days</p></td><td style="vertical-align:top"><p>&uarr; 15%</p></td><td style="vertical-align:top"><p>Patients taking digoxin should be monitored</p><p>appropriately.</p></td></tr><tr><td style="vertical-align:top"><p>40 mg OD for 22 days</p></td><td style="vertical-align:top"><p>Oral contraceptive OD, 2 months</p><p>-norethisterone 1 mg</p><p>-ethinyl estradiol 35 &mu;g</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&uarr; 28%</p><p>&uarr; 19%</p></td><td style="vertical-align:top"><p>No specific recommendation.</p></td></tr><tr><td style="vertical-align:top"><p>80 mg OD for 15 days</p></td><td style="vertical-align:top"><p>* Phenazone, 600 mg SD</p></td><td style="vertical-align:top"><p>&uarr; 3%</p></td><td style="vertical-align:top"><p>No specific recommendation</p></td></tr><tr><td style="vertical-align:top"><p>10 mg OD for 4 days</p></td><td style="vertical-align:top"><p>Fosamprenavir 1400 mg</p><p>BID, 14 days</p></td><td style="vertical-align:top"><p>&darr; 27%</p></td><td style="vertical-align:top"><p>No specific recommendation</p></td></tr></tbody></table><p>&amp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Data given as % change represent % difference relative to atorvastatin alone (i.e., 0% = no change)</p><p>*&nbsp;&nbsp;&nbsp;&nbsp; Co-administration of multiple doses of atorvastatin and phenazone showed little or no detectable effect in the clearance of phenazone.</p><p>Increase is indicated as &ldquo;&uarr;&rdquo;, decrease as &ldquo;&darr;&rdquo;</p><p>OD = once daily; SD = single dose; BID = twice daily</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Women of childbearing potential</em></p><p>Women of childbearing potential should use appropriate contraceptive measures during treatment (see section 4.3).</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>Atherosclerosis is a chronic process, and ordinarily discontinuation of lipid-lowering drugs during pregnancy should have little impact on the long-term risk associated with primary hypercholesterolaemia.</p><p>&nbsp;</p><p><em>ATOZET</em></p><p>ATOZET is contraindicated during pregnancy (see section 4.3). No clinical data are available on the use of ATOZET during pregnancy. ATOZET should not be used in women who are pregnant, trying to become pregnant or suspect they are pregnant. Treatment with ATOZET should be suspended for the duration of pregnancy or until it has been determined that the woman is not pregnant (see section 4.3).</p><p>&nbsp;</p><p>&nbsp;</p><p>The co-administration of ezetimibe and atorvastatin in pregnant rats indicated that there was a test article- related increase in the skeletal variation &ldquo;reduced ossification of the sternebrae&rdquo; in the high dose ezetimibe/atorvastatin group. This may be related to the observed decrease in foetal body weights. In pregnant rabbits a low incidence of skeletal deformities (fused sternebrae, fused caudal vertebrae and asymmetrical sternebrae variation) were observed.</p><p>&nbsp;</p><p><em>Atorvastatin</em></p><p>Safety in pregnant women has not been established. No controlled clinical trials with atorvastatin have been conducted in pregnant women. Rare reports of congenital anomalies following intrauterine exposure to HMG-CoA reductase inhibitors have been received. Animal studies have shown toxicity to reproduction (see section 5.3). Maternal treatment with atorvastatin may reduce the foetal levels of mevalonate which is a precursor of cholesterol biosynthesis.</p><p>&nbsp;</p><p><em>Ezetimibe</em></p><p>No clinical data are available on the use of ezetimibe during pregnancy. Animal studies on the use of ezetimibe in monotherapy have shown no evidence of direct or indirect harmful effects on pregnancy, embryofoetal development, birth or postnatal development (see section 5.3).</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>ATOZET is contraindicated during breast-feeding. Because of the potential for serious adverse reactions, women taking ATOZET should not breast-feed their infants. Studies on rats have shown that ezetimibe is secreted into breast milk. In rats, plasma concentrations of atorvastatin and its active metabolites are similar to those in milk. It is not known if the active components of ATOZET are secreted into human breast milk. (See section 4.3.)</p><p>&nbsp;</p><p><u>Fertility</u></p><p>No fertility studies were conducted with ATOZET.</p><p>&nbsp;</p><p><em>Atorvastatin</em></p><p>In animal studies atorvastatin had no effect on male or female fertility.</p><p>&nbsp;</p><p><em>Ezetimibe</em></p><p>Ezetimibe had no effect on the fertility of male or female rats.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATOZET has negligible influence on the ability to drive and use machines. However, when driving vehicles or operating machines, it should be taken into account that dizziness has been reported.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p><u>Summary of the safety profile</u></p><p>ATOZET (or co-administration of ezetimibe and atorvastatin equivalent to ATOZET) has been evaluated for safety in more than 2400 patients in 7 clinical trials.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Adverse reactions observed in clinical studies of ATOZET (or co-administration of ezetimibe and atorvastatin equivalent to ATOZET) or ezetimibe or atorvastatin or reported from post-marketing use with ATOZET or ezetimibe or atorvastatin are listed in Table 3. These reactions are presented by system organ class and by frequency. Frequencies are defined as: very common (&sup3;1/10); common &sup3;1/100,</p><p>&lt;1/10); uncommon (&sup3;1/1000, &lt;1/100); rare (&sup3;1/10,000, &lt;1/1000); very rare (&lt;1/10,000); and not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>Table 3 Adverse Reactions</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p><p>Frequency</p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>influenza</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>nasopharyngitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>thrombocytopaenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>hypersensitivity, including anaphylaxis, angioedema,</p><p>rash, and urticaria</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>decreased appetite; anorexia; hyperglycaemia;</p><p>hypoglycaemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>depression; insomnia; sleep disorder</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>nightmares</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>dizziness; dysgeusia; headache; paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>hypoesthesia; amnesia; peripheral neuropathy</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>vision blurred; visual disturbance</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>tinnitus; hearing loss</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>sinus bradycardia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>hot flush</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>hypertension</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>dyspnoea</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>cough; pharyngolaryngeal pain; epistaxis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>abdominal discomfort; abdominal distension; abdominal pain; abdominal pain lower; abdominal pain upper; constipation; dyspepsia; flatulence; frequent bowel movements; gastritis; nausea; stomach</p><p>discomfort</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>pancreatitis; gastro-oesophageal reflux disease;</p><p>eructation; vomiting; dry mouth</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>hepatitis; cholelithiasis; cholecystitis; cholestasis; fatal</p><p>and non-fatal hepatic failure</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>acne; urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>alopecia; skin rash; pruritus; erythema multiforme; angioneurotic oedema; dermatitis bullous including erythema multiforme, Stevens-Johnson syndrome and</p><p>toxic epidermal necrolysis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>arthralgia; back pain; muscle fatigue; muscle spasms;</p><p>muscular weakness; pain in extremity</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>myopathy/rhabdomyolysis; muscle rupture; tendinopathy, sometimes complicated by rupture; neck pain; joint swelling; myositis; lupus-like syndrome; immune-mediated necrotizing myopathy (see section</p><p>4.4)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>gynacomastia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>asthenia; fatigue; malaise; oedema</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>chest pain; pain; peripheral oedema; pyrexia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>ALT and/or AST increased; alkaline phosphatase increased; blood creatine phosphokinase (CPK) increased; gamma-glutamyltransferase increased; hepatic enzyme increased; liver function test abnormal;</p><p>weight increased</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>white blood cells urine positive</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>Laboratory Values</u></p><p>In controlled clinical trials, the incidence of clinically important elevations in serum transaminases (ALT and/or AST &sup3;3 X ULN, consecutive) was 0.6% for patients treated with ATOZET. These elevations were generally asymptomatic, not associated with cholestasis, and returned to baseline spontaneously or after discontinuation of therapy (see section 4.4.).</p><p>&nbsp;</p><p>The following adverse events have been reported with some statins:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sexual dysfunction</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; exceptional cases of interstitial lung disease, especially with long term therapy (see section 4.4)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diabetes mellitus: frequency will depend on the presence or absence of risk factors (fasting blood glucose &ge;5.6 mmol/L, BMI&gt;30kg/m<sup>2</sup>, raised triglycerides, history of hypertension)</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <u>Saudi Arabia: </u></p><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other GCC States: </u></p><p>Please contact the relevant competent authority.</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>ATOZET</em></p><p>In the event of an overdose, symptomatic and supportive measures should be employed. Liver function tests should be performed and serum CPK levels should be monitored.</p><p>&nbsp;</p><p><em>Ezetimibe</em></p><p>In clinical studies, administration of ezetimibe, 50 mg/day to 15 healthy subjects for up to 14 days, or</p><p>40 mg/day to 18 patients with primary hyperlipidaemia for up to 56 days, was generally well tolerated. A few cases of overdose have been reported; most have not been associated with adverse experiences.</p><p>Reported adverse experiences have not been serious. In animals, no toxicity was observed after single oral doses of 5000 mg/kg of ezetimibe in rats and mice and 3000 mg/kg in dogs.</p><p>&nbsp;</p><p><em>Atorvastatin</em></p><p>Due to extensive atorvastatin binding to plasma proteins, haemodialysis is not expected to significantly enhance atorvastatin clearance.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Lipid modifying agents, HMG-CoA reductase inhibitors in combination with other lipid modifying agents, ATC code: C10BA05</p><p>&nbsp;</p><p>ATOZET (ezetimibe/atorvastatin) is a lipid-lowering product that selectively inhibits the intestinal absorption of cholesterol and related plant sterols and inhibits the endogenous synthesis of cholesterol.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p><em>ATOZET</em></p><p>Plasma cholesterol is derived from intestinal absorption and endogenous synthesis. ATOZET contains ezetimibe and atorvastatin, two lipid-lowering compounds with complementary mechanisms of action. ATOZET reduces elevated total cholesterol (total-C), LDL-C, apolipoprotein B (Apo B), triglycerides (TG), and non-high-density lipoprotein cholesterol (non-HDL-C), and increases high-density lipoprotein cholesterol (HDL-C) through dual inhibition of cholesterol absorption and synthesis.</p><p>&nbsp;</p><p><em>Ezetimibe</em></p><p>Ezetimibe inhibits the intestinal absorption of cholesterol. Ezetimibe is orally active and has a mechanism of action that differs from other classes of cholesterol-reducing compounds (e.g., statins, bile acid</p><p>&nbsp;</p><p>sequestrants [resins], fibric acid derivatives, and plant stanols). The molecular target of ezetimibe is the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is responsible for the intestinal uptake of cholesterol and phytosterols.</p><p>&nbsp;</p><p>Ezetimibe localises at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver; statins reduce cholesterol synthesis in the liver and together these distinct mechanisms provide complementary cholesterol reduction. In a 2-week clinical study in 18 hypercholesterolaemic patients, ezetimibe inhibited intestinal cholesterol absorption by 54%, compared with placebo.</p><p>&nbsp;</p><p>A series of preclinical studies was performed to determine the selectivity of ezetimibe for inhibiting cholesterol absorption. Ezetimibe inhibited the absorption of [<sup>14</sup>C]-cholesterol with no effect on the absorption of triglycerides, fatty acids, bile acids, progesterone, ethinyl estradiol, or fat soluble vitamins A and D.</p><p>&nbsp;</p><p><em>Atorvastatin</em></p><p>Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme responsible for the conversion of 3-hydroxy-3-methyl-glutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. Triglycerides and cholesterol in the liver are incorporated into very low- density lipoproteins (VLDL) and released into the plasma for delivery to peripheral tissues. Low-density lipoprotein (LDL) is formed from VLDL and is catabolised primarily through the receptor with high affinity to LDL (LDL receptor).</p><p>&nbsp;</p><p>Atorvastatin lowers plasma cholesterol and lipoprotein serum concentrations by inhibiting HMG-CoA reductase and subsequently cholesterol biosynthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.</p><p>&nbsp;</p><p>Atorvastatin reduces LDL production and the number of LDL particles. Atorvastatin produces a profound and sustained increase in LDL receptor activity coupled with a beneficial change in the quality of circulating LDL particles. Atorvastatin is effective in reducing LDL-C in patients with homozygous familial hypercholesterolaemia, a population that has not usually responded to lipid-lowering medicinal products.</p><p>&nbsp;</p><p>Atorvastatin has been shown to reduce concentrations of total-C (30% - 46%), LDL-C (41% - 61%), apolipoprotein B (34% - 50%), and triglycerides (14% - 33%) while producing variable increases in HDL-C and apolipoprotein A1 in a dose response study. These results are consistent in patients with heterozygous familial hypercholesterolaemia, nonfamilial forms of hypercholesterolaemia, and mixed hyperlipidaemia, including patients with noninsulin-dependent diabetes mellitus.</p><p>&nbsp;</p><p>Clinical efficacy and safety</p><p>&nbsp;</p><p>In controlled clinical studies, ATOZET significantly reduced total-C, LDL-C, Apo B, and TG, and increased HDL-C in patients with hypercholesterolaemia.</p><p>&nbsp;</p><p><em>Primary Hypercholesterolaemia</em></p><p>In a placebo-controlled study, 628 patients with hyperlipidaemia were randomised to receive placebo, ezetimibe (10 mg), atorvastatin (10 mg, 20 mg, 40 mg, or 80 mg), or co-administered ezetimibe and atorvastatin equivalent to ATOZET (10/10, 10/20, 10/40, and 10/80) for up to 12-weeks .</p><p>&nbsp;</p><p>Patients receiving all doses of ATOZET were compared to those receiving all doses of atorvastatin. ATOZET lowered total-C, LDL-C, Apo B, TG, and non-HDL-C, and increased HDL-C significantly more than atorvastatin alone (see Table 4).</p><p>Table 4</p><p><strong>Response to ATOZET in Patients with Primary Hyperlipidaemia (Mean<sup>a</sup> % Change from Untreated Baseline<sup>b</sup> at 12 weeks)</strong></p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_76" o:spid="_x0000_s1089"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:67.9pt;margin-top:-2.75pt;width:475.45pt;height:241.45pt;
 z-index:251666432;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Treatment&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; N</strong></p></td><td style="vertical-align:top"><p><strong>Total-C</strong></p></td><td style="vertical-align:top"><p><strong>LDL-C</strong></p></td><td style="vertical-align:top"><p><strong>Apo B</strong></p></td><td style="vertical-align:top"><p><strong>TG<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>HDL-C</strong></p></td><td style="vertical-align:top"><p><strong>Non-HDL-C</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pooled data (All ATOZET&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 255</p></td><td style="vertical-align:top"><p>-41</p></td><td style="vertical-align:top"><p>-56</p></td><td style="vertical-align:top"><p>-45</p></td><td style="vertical-align:top"><p>-33</p></td><td style="vertical-align:top"><p>+7</p></td><td style="vertical-align:top"><p>-52</p></td></tr><tr><td style="vertical-align:top"><p>Pooled data (All atorvastatin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 248</p></td><td style="vertical-align:top"><p>-32</p></td><td style="vertical-align:top"><p>-44</p></td><td style="vertical-align:top"><p>-36</p></td><td style="vertical-align:top"><p>-24</p></td><td style="vertical-align:top"><p>+4</p></td><td style="vertical-align:top"><p>-41</p></td></tr><tr><td style="vertical-align:top"><p>Ezetimibe 10 mg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 65</p></td><td style="vertical-align:top"><p>-14</p></td><td style="vertical-align:top"><p>-20</p></td><td style="vertical-align:top"><p>-15</p></td><td style="vertical-align:top"><p>-5</p></td><td style="vertical-align:top"><p>+4</p></td><td style="vertical-align:top"><p>-18</p></td></tr><tr><td style="vertical-align:top"><p>Placebo&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 60</p></td><td style="vertical-align:top"><p>+4</p></td><td style="vertical-align:top"><p>+4</p></td><td style="vertical-align:top"><p>+3</p></td><td style="vertical-align:top"><p>-6</p></td><td style="vertical-align:top"><p>+4</p></td><td style="vertical-align:top"><p>+4</p></td></tr><tr><td style="vertical-align:top"><p>ATOZET by dose</p><p>10/10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 65</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-38</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-53</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-43</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-31</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>+9</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-49</p></td></tr><tr><td style="vertical-align:top"><p>10/20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 62</p></td><td style="vertical-align:top"><p>-39</p></td><td style="vertical-align:top"><p>-54</p></td><td style="vertical-align:top"><p>-44</p></td><td style="vertical-align:top"><p>-30</p></td><td style="vertical-align:top"><p>+9</p></td><td style="vertical-align:top"><p>-50</p></td></tr><tr><td style="vertical-align:top"><p>10/40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 65</p></td><td style="vertical-align:top"><p>-42</p></td><td style="vertical-align:top"><p>-56</p></td><td style="vertical-align:top"><p>-45</p></td><td style="vertical-align:top"><p>-34</p></td><td style="vertical-align:top"><p>+5</p></td><td style="vertical-align:top"><p>-52</p></td></tr><tr><td style="vertical-align:top"><p>10/80&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 63</p></td><td style="vertical-align:top"><p>-46</p></td><td style="vertical-align:top"><p>-61</p></td><td style="vertical-align:top"><p>-50</p></td><td style="vertical-align:top"><p>-40</p></td><td style="vertical-align:top"><p>+7</p></td><td style="vertical-align:top"><p>-58</p></td></tr><tr><td style="vertical-align:top"><p>Atorvastatin by dose</p><p>10 mg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 60</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-26</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-37</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-28</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-21</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>+6</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-34</p></td></tr><tr><td style="vertical-align:top"><p>20 mg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 60</p></td><td style="vertical-align:top"><p>-30</p></td><td style="vertical-align:top"><p>-42</p></td><td style="vertical-align:top"><p>-34</p></td><td style="vertical-align:top"><p>-23</p></td><td style="vertical-align:top"><p>+4</p></td><td style="vertical-align:top"><p>-39</p></td></tr><tr><td style="vertical-align:top"><p>40 mg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 66</p></td><td style="vertical-align:top"><p>-32</p></td><td style="vertical-align:top"><p>-45</p></td><td style="vertical-align:top"><p>-37</p></td><td style="vertical-align:top"><p>-24</p></td><td style="vertical-align:top"><p>+4</p></td><td style="vertical-align:top"><p>-41</p></td></tr><tr><td style="vertical-align:top"><p>80 mg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 62</p></td><td style="vertical-align:top"><p>-40</p></td><td style="vertical-align:top"><p>-54</p></td><td style="vertical-align:top"><p>-46</p></td><td style="vertical-align:top"><p>-31</p></td><td style="vertical-align:top"><p>+3</p></td><td style="vertical-align:top"><p>-51</p></td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p><strong>(Daily Dose)</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>doses)<sup>c</sup> doses)<sup>c</sup></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><o:wrapblock><v:group
  id="Group_x0020_67" o:spid="_x0000_s1080" style='position:absolute;
  margin-left:68.65pt;margin-top:8.2pt;width:474.75pt;height:.5pt;z-index:-251657216;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="1373,164" coordsize="9495,10"
  o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF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">
  <v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75"
   o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="Picture_x0020_75" o:spid="_x0000_s1081" type="#_x0000_t75"
   style='position:absolute;left:1372;top:164;width:2736;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
    o:title=""/>
  </v:shape><v:shape id="Picture_x0020_74" o:spid="_x0000_s1082" type="#_x0000_t75"
   style='position:absolute;left:4108;top:164;width:807;height:10;visibility:visible;
   mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBnNE9YxAAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9fa8Iw
FMXfB36HcIW9zbRjFFeNRQfC9jBlVcHHS3NNi81NaTKt+/SLMNjj4fz5cebFYFtxod43jhWkkwQE
ceV0w0bBfrd+moLwAVlj65gU3MhDsRg9zDHX7spfdCmDEXGEfY4K6hC6XEpf1WTRT1xHHL2T6y2G
KHsjdY/XOG5b+ZwkmbTYcCTU2NFbTdW5/LZ3yHGbvKxun+ufss0+NgeTnqZGqcfxsJyBCDSE//Bf
+10ryF7h/iX+ALn4BQAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAA
AAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsA
AAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAGc0T1jEAAAA2wAAAA8A
AAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD4AgAAAAA=
">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png"
    o:title=""/>
  </v:shape><v:shape id="Picture_x0020_73" o:spid="_x0000_s1083" type="#_x0000_t75"
   style='position:absolute;left:4915;top:164;width:1056;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
    o:title=""/>
  </v:shape><v:shape id="Picture_x0020_72" o:spid="_x0000_s1084" type="#_x0000_t75"
   style='position:absolute;left:5971;top:164;width:3444;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image004.png"
    o:title=""/>
  </v:shape><v:rect id="Rectangle_x0020_71" o:spid="_x0000_s1085" style='position:absolute;
   left:8407;top:164;width:8;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_70" o:spid="_x0000_s1086" style='position:absolute;
   left:8414;top:164;width:10;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:shape id="Picture_x0020_69" o:spid="_x0000_s1087" type="#_x0000_t75"
   style='position:absolute;left:9415;top:164;width:1450;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBAt0q0xAAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ba8JA
FITvgv9heUJvujEUa1NXkUKhVCKoFTw+sq/ZYPZtyG6TtL++WxA8DjPzDbPaDLYWHbW+cqxgPktA
EBdOV1wq+Dy9TZcgfEDWWDsmBT/kYbMej1aYadfzgbpjKEWEsM9QgQmhyaT0hSGLfuYa4uh9udZi
iLItpW6xj3BbyzRJFtJixXHBYEOvhorr8dsqYMybj+fO7GSe7vfFb5hfdH5W6mEybF9ABBrCPXxr
v2sFT4/w/yX+ALn+AwAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAA
AAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsA
AAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAEC3SrTEAAAA2wAAAA8A
AAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD4AgAAAAA=
">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image005.png"
    o:title=""/>
  </v:shape><v:rect id="Rectangle_x0020_68" o:spid="_x0000_s1088" style='position:absolute;
   left:10864;top:164;width:3;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><v:group id="Group_x0020_58" o:spid="_x0000_s1071" style='position:absolute;
  margin-left:68.65pt;margin-top:21.65pt;width:474.75pt;height:.5pt;z-index:-251656192;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="1373,433" coordsize="9495,10"
  o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF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">
  <v:shape id="Picture_x0020_66" o:spid="_x0000_s1072" type="#_x0000_t75"
   style='position:absolute;left:1372;top:432;width:2736;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
    o:title=""/>
  </v:shape><v:shape id="Picture_x0020_65" o:spid="_x0000_s1073" type="#_x0000_t75"
   style='position:absolute;left:4108;top:432;width:807;height:10;visibility:visible;
   mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image006.png"
    o:title=""/>
  </v:shape><v:shape id="Picture_x0020_64" o:spid="_x0000_s1074" type="#_x0000_t75"
   style='position:absolute;left:4915;top:432;width:1056;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image007.png"
    o:title=""/>
  </v:shape><v:shape id="Picture_x0020_63" o:spid="_x0000_s1075" type="#_x0000_t75"
   style='position:absolute;left:5971;top:432;width:3444;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image008.png"
    o:title=""/>
  </v:shape><v:rect id="Rectangle_x0020_62" o:spid="_x0000_s1076" style='position:absolute;
   left:8407;top:432;width:8;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_61" o:spid="_x0000_s1077" style='position:absolute;
   left:8414;top:432;width:10;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:shape id="Picture_x0020_60" o:spid="_x0000_s1078" type="#_x0000_t75"
   style='position:absolute;left:9415;top:432;width:1450;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image009.png"
    o:title=""/>
  </v:shape><v:rect id="Rectangle_x0020_59" o:spid="_x0000_s1079" style='position:absolute;
   left:10864;top:432;width:3;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><v:group id="Group_x0020_49" o:spid="_x0000_s1062" style='position:absolute;
  margin-left:68.65pt;margin-top:35.2pt;width:474.75pt;height:.5pt;z-index:-251655168;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="1373,704" coordsize="9495,10"
  o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF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">
  <v:shape id="Picture_x0020_57" o:spid="_x0000_s1063" type="#_x0000_t75"
   style='position:absolute;left:1372;top:704;width:2736;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
    o:title=""/>
  </v:shape><v:shape id="Picture_x0020_56" o:spid="_x0000_s1064" type="#_x0000_t75"
   style='position:absolute;left:4108;top:704;width:807;height:10;visibility:visible;
   mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png"
    o:title=""/>
  </v:shape><v:shape id="Picture_x0020_55" o:spid="_x0000_s1065" type="#_x0000_t75"
   style='position:absolute;left:4915;top:704;width:1056;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
    o:title=""/>
  </v:shape><v:shape id="Picture_x0020_54" o:spid="_x0000_s1066" type="#_x0000_t75"
   style='position:absolute;left:5971;top:704;width:3444;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image004.png"
    o:title=""/>
  </v:shape><v:rect id="Rectangle_x0020_53" o:spid="_x0000_s1067" style='position:absolute;
   left:8407;top:704;width:8;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_52" o:spid="_x0000_s1068" style='position:absolute;
   left:8414;top:704;width:10;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:shape id="Picture_x0020_51" o:spid="_x0000_s1069" type="#_x0000_t75"
   style='position:absolute;left:9415;top:704;width:1450;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image005.png"
    o:title=""/>
  </v:shape><v:rect id="Rectangle_x0020_50" o:spid="_x0000_s1070" style='position:absolute;
   left:10864;top:704;width:3;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="633" height="1" src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image010.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><o:wrapblock><v:group
  id="Group_x0020_40" o:spid="_x0000_s1053" style='position:absolute;
  margin-left:68.65pt;margin-top:14.55pt;width:474.75pt;height:.5pt;z-index:-251654144;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="1373,291" coordsize="9495,10"
  o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF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">
  <v:shape id="Picture_x0020_48" o:spid="_x0000_s1054" type="#_x0000_t75"
   style='position:absolute;left:1372;top:290;width:2736;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
    o:title=""/>
  </v:shape><v:shape id="Picture_x0020_47" o:spid="_x0000_s1055" type="#_x0000_t75"
   style='position:absolute;left:4108;top:290;width:807;height:10;visibility:visible;
   mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png"
    o:title=""/>
  </v:shape><v:shape id="Picture_x0020_46" o:spid="_x0000_s1056" type="#_x0000_t75"
   style='position:absolute;left:4915;top:290;width:1056;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCSQkHTxAAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/dasJA
FITvhb7Dcgre6cYfRKKrlBRBIhWMfYDT7DEJZs+G3VXTPn23UPBymJlvmPW2N624k/ONZQWTcQKC
uLS64UrB53k3WoLwAVlja5kUfJOH7eZlsMZU2wef6F6ESkQI+xQV1CF0qZS+rMmgH9uOOHoX6wyG
KF0ltcNHhJtWTpNkIQ02HBdq7CirqbwWN6OgeM9mH5ciP2b5pOL8Z+fwsPxSavjav61ABOrDM/zf
3msF8xn8fYk/QG5+AQAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAA
AAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsA
AAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAJJCQdPEAAAA2wAAAA8A
AAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD4AgAAAAA=
">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
    o:title=""/>
  </v:shape><v:shape id="Picture_x0020_45" o:spid="_x0000_s1057" type="#_x0000_t75"
   style='position:absolute;left:5971;top:290;width:3444;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image004.png"
    o:title=""/>
  </v:shape><v:rect id="Rectangle_x0020_44" o:spid="_x0000_s1058" style='position:absolute;
   left:8407;top:290;width:8;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_43" o:spid="_x0000_s1059" style='position:absolute;
   left:8414;top:290;width:10;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:shape id="Picture_x0020_42" o:spid="_x0000_s1060" type="#_x0000_t75"
   style='position:absolute;left:9415;top:290;width:1450;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image005.png"
    o:title=""/>
  </v:shape><v:rect id="Rectangle_x0020_41" o:spid="_x0000_s1061" style='position:absolute;
   left:10864;top:290;width:3;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><v:group id="Group_x0020_31" o:spid="_x0000_s1044" style='position:absolute;
  margin-left:68.65pt;margin-top:28.1pt;width:474.75pt;height:.5pt;z-index:-251653120;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="1373,562" coordsize="9495,10"
  o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF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=
">
  <v:shape id="Picture_x0020_39" o:spid="_x0000_s1045" type="#_x0000_t75"
   style='position:absolute;left:1372;top:561;width:2736;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
    o:title=""/>
  </v:shape><v:shape id="Picture_x0020_38" o:spid="_x0000_s1046" type="#_x0000_t75"
   style='position:absolute;left:4108;top:561;width:807;height:10;visibility:visible;
   mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image006.png"
    o:title=""/>
  </v:shape><v:shape id="Picture_x0020_37" o:spid="_x0000_s1047" type="#_x0000_t75"
   style='position:absolute;left:4915;top:561;width:1056;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image007.png"
    o:title=""/>
  </v:shape><v:shape id="Picture_x0020_36" o:spid="_x0000_s1048" type="#_x0000_t75"
   style='position:absolute;left:5971;top:561;width:3444;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image008.png"
    o:title=""/>
  </v:shape><v:rect id="Rectangle_x0020_35" o:spid="_x0000_s1049" style='position:absolute;
   left:8407;top:561;width:8;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_34" o:spid="_x0000_s1050" style='position:absolute;
   left:8414;top:561;width:10;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:shape id="Picture_x0020_33" o:spid="_x0000_s1051" type="#_x0000_t75"
   style='position:absolute;left:9415;top:561;width:1450;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image009.png"
    o:title=""/>
  </v:shape><v:rect id="Rectangle_x0020_32" o:spid="_x0000_s1052" style='position:absolute;
   left:10864;top:561;width:3;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><v:group id="Group_x0020_22" o:spid="_x0000_s1035" style='position:absolute;
  margin-left:68.65pt;margin-top:41.55pt;width:474.75pt;height:.5pt;z-index:-251652096;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="1373,831" coordsize="9495,10"
  o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF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">
  <v:shape id="Picture_x0020_30" o:spid="_x0000_s1036" type="#_x0000_t75"
   style='position:absolute;left:1372;top:830;width:2736;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAwR/LSxQAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/NasMw
EITvhbyD2EJvjdwUQnEjmzQ/UJJL7PaS28ba2sbWyliK7b59FCj0OMzMN8wqnUwrBupdbVnByzwC
QVxYXXOp4Ptr//wGwnlkja1lUvBLDtJk9rDCWNuRMxpyX4oAYRejgsr7LpbSFRUZdHPbEQfvx/YG
fZB9KXWPY4CbVi6iaCkN1hwWKuxoU1HR5FejwJ/W2bk8fhw2x0t9crttI/dto9TT47R+B+Fp8v/h
v/anVrB4hfuX8ANkcgMAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAA
AAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAAL
AAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQAwR/LSxQAAANsAAAAP
AAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA+QIAAAAA
">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
    o:title=""/>
  </v:shape><v:shape id="Picture_x0020_29" o:spid="_x0000_s1037" type="#_x0000_t75"
   style='position:absolute;left:4108;top:830;width:807;height:10;visibility:visible;
   mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png"
    o:title=""/>
  </v:shape><v:shape id="Picture_x0020_28" o:spid="_x0000_s1038" type="#_x0000_t75"
   style='position:absolute;left:4915;top:830;width:1056;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
    o:title=""/>
  </v:shape><v:shape id="Picture_x0020_27" o:spid="_x0000_s1039" type="#_x0000_t75"
   style='position:absolute;left:5971;top:830;width:3444;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image004.png"
    o:title=""/>
  </v:shape><v:rect id="Rectangle_x0020_26" o:spid="_x0000_s1040" style='position:absolute;
   left:8407;top:830;width:8;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_25" o:spid="_x0000_s1041" style='position:absolute;
   left:8414;top:830;width:10;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:shape id="Picture_x0020_24" o:spid="_x0000_s1042" type="#_x0000_t75"
   style='position:absolute;left:9415;top:830;width:1450;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image005.png"
    o:title=""/>
  </v:shape><v:rect id="Rectangle_x0020_23" o:spid="_x0000_s1043" style='position:absolute;
   left:10864;top:830;width:3;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><v:group id="Group_x0020_13" o:spid="_x0000_s1026" style='position:absolute;
  margin-left:68.65pt;margin-top:55.1pt;width:474.75pt;height:.5pt;z-index:-251651072;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="1373,1102" coordsize="9495,10"
  o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF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">
  <v:shape id="Picture_x0020_21" o:spid="_x0000_s1027" type="#_x0000_t75"
   style='position:absolute;left:1372;top:1101;width:2736;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
    o:title=""/>
  </v:shape><v:shape id="Picture_x0020_20" o:spid="_x0000_s1028" type="#_x0000_t75"
   style='position:absolute;left:4108;top:1101;width:807;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image006.png"
    o:title=""/>
  </v:shape><v:shape id="Picture_x0020_19" o:spid="_x0000_s1029" type="#_x0000_t75"
   style='position:absolute;left:4915;top:1101;width:1056;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image007.png"
    o:title=""/>
  </v:shape><v:shape id="Picture_x0020_18" o:spid="_x0000_s1030" type="#_x0000_t75"
   style='position:absolute;left:5971;top:1101;width:3444;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image008.png"
    o:title=""/>
  </v:shape><v:rect id="Rectangle_x0020_17" o:spid="_x0000_s1031" style='position:absolute;
   left:8407;top:1101;width:8;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBX2SJkxgAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Pb8Iw
DMXvSPsOkSdxg3SIIdYREEyatMuk8ecAN9N4bUXjlCSDbp9+PiBxs/We3/t5tuhcoy4UYu3ZwNMw
A0VceFtzaWC3fR9MQcWEbLHxTAZ+KcJi/tCbYW79ldd02aRSSQjHHA1UKbW51rGoyGEc+pZYtG8f
HCZZQ6ltwKuEu0aPsmyiHdYsDRW29FZRcdr8OAOrl+nq/DXmz7/18UCH/fH0PAqZMf3HbvkKKlGX
7ubb9YcVfIGVX2QAPf8HAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAA
AAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAA
CwAAAAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAV9kiZMYAAADbAAAA
DwAAAAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPoCAAAAAA==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_16" o:spid="_x0000_s1032" style='position:absolute;
   left:8414;top:1101;width:10;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:shape id="Picture_x0020_15" o:spid="_x0000_s1033" type="#_x0000_t75"
   style='position:absolute;left:9415;top:1101;width:1450;height:10;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
   <v:imagedata src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image009.png"
    o:title=""/>
  </v:shape><v:rect id="Rectangle_x0020_14" o:spid="_x0000_s1034" style='position:absolute;
   left:10864;top:1101;width:3;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="633" height="1" src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image011.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>a For triglycerides, median % change from baseline</p><p>b&nbsp; Baseline - on no lipid-lowering medicinal product</p><p>c ATOZET pooled (10/10-10/80 mg) significantly reduced total-C, LDL-C, Apo B, TG,</p><p>non-HDL-C, and significantly increased HDL-C compared to all doses of atorvastatin pooled (10-80 mg).</p><p>&nbsp;</p><p>In a controlled study, the Titration of Atorvastatin vs Ezetimibe Add-On to Atorvastatin in Patients with Hypercholesterolaemia (TEMPO) study, 184 patients, with an LDL-C level &sup3;2.6 mmol/L and</p><p>&pound;4.1 mmol/L and at moderate high risk for CHD, received atorvastatin 20 mg for a minimum of 4 weeks prior to randomisation. Patients not at an LDL-C level &lt;2.6 mmol/L were randomised to receive either co-administered ezetimibe and atorvastatin (equivalent to ATOZET 10/20) or atorvastatin 40 mg for</p><p>6 weeks.</p><p>&nbsp;</p><p>ATOZET 10/20 was significantly more effective than doubling the dose of atorvastatin to 40 mg in further reducing total-C (-20% vs. -7%), LDL-C (-31% vs. -11%), Apo B (-21% vs. -8%), and non-HDL- C (-27% vs. -10%). Results for HDL-C and TG between the two treatment groups were not significantly different. Also, significantly more patients receiving ATOZET 10/20 attained LDL-C &lt;2.6 mmol/L compared to those receiving atorvastatin 40 mg, 84% vs. 49%.</p><p>&nbsp;</p><p>In a controlled study, The Ezetimibe Plus Atorvastatin vs Atorvastatin Titration in Achieving Lower LDL-C Targets in Hypercholesterolaemic Patients (EZ-PATH) study, 556 high-cardiovascular-risk patients with a LDL-C level &sup3;1.8 mmol/L and &pound;4.1 mmol/L received atorvastatin 40 mg for a minimum of 4 weeks prior to randomisation. Patients not at a LDL-C level &lt;1.8 mmol/L were randomised to</p><p>&nbsp;</p><p>receive either co-administered ezetimibe and atorvastatin (equivalent to ATOZET 10/40) or atorvastatin 80 mg for 6 weeks.</p><p>&nbsp;</p><p>ATOZET 10/40 was significantly more effective than doubling the dose of atorvastatin to 80 mg in further reducing total-C (-17% vs. -7%), LDL-C (-27% vs. -11%), Apo B (-18% vs. -8%), TG (-12% vs.</p><p>-6%), and non-HDL-C (-23% vs. -9%). Results for HDL-C between the two treatment groups were not significantly different. Also, significantly more patients receiving ATOZET 10/40 attained LDL-C</p><p>&lt;1.8 mmol/L compared to those receiving atorvastatin 80 mg, 74% vs. 32%.</p><p>&nbsp;</p><p>In a placebo-controlled, 8-week study, 308 hypercholesterolaemic patients receiving atorvastatin and not at National Cholesterol Education Program (NCEP) LDL-C goal (LDL-C goal based upon baseline LDL- C and CHD risk status) were randomised to receive either ezetimibe 10 mg or placebo in addition to their on-going atorvastatin therapy.</p><p>&nbsp;</p><p>Among patients not at LDL-C goal at baseline (~83%), significantly more patients receiving ezetimibe co-administered with atorvastatin achieved their LDL-C goal compared to patients receiving placebo co- administered with atorvastatin, 67% vs. 19%. Ezetimibe added to atorvastatin therapy lowered LDL-C significantly more than placebo added to atorvastatin therapy, 25% vs. 4%. Ezetimibe added to atorvastatin therapy also significantly decreased total-C, Apo B, and TG compared with placebo added to atorvastatin therapy.</p><p>&nbsp;</p><p>In a controlled, 12-week, 2-phase study, 1539 high-cardiovascular-risk patients, with a LDL-C level between 2.6 and 4.1 mmol/L, on atorvastatin 10 mg daily were randomised to receive: atorvastatin 20 mg, rosuvastatin 10 mg, or ATOZET 10/10. After 6 weeks of treatment (Phase I), patients taking atorvastatin 20 mg who failed to achieve a LDL-C level &lt;2.6 mmol/L were switched to either atorvastatin 40 mg or ATOZET 10/20 for 6 weeks (Phase II), and similar patients taking rosuvastatin 10 mg during Phase I were switched to either rosuvastatin 20 mg or ATOZET 10/20. Reductions in LDL-C and comparisons between the ATOZET group and other treatment groups studied are shown in Table 5.</p><p>Table 5</p><p><strong>Response to ATOZET* in High-Risk Patients with a LDL-C Level Between 2.6 and 4.1 mmol/L on Atorvastatin 10 mg Daily at Baseline</strong></p><p><strong>Treatment&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; N&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Percent Change from Baseline<sup>&dagger;</sup></strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Total-C</p></td><td style="vertical-align:top"><p>LDL-C</p></td><td style="vertical-align:top"><p>Apo B</p></td><td style="vertical-align:top"><p>TG<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>HDL-C</p></td><td style="vertical-align:top"><p>Non-HDL-C</p></td></tr><tr><td style="vertical-align:top"><p><strong>Phase I</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Switched from atorvastatin</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>10 mg</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ATOZET 10/10 120</p></td><td style="vertical-align:top"><p>-13.5</p></td><td style="vertical-align:top"><p>-22.2</p></td><td style="vertical-align:top"><p>-11.3</p></td><td style="vertical-align:top"><p>-6.0</p></td><td style="vertical-align:top"><p>+0.6</p></td><td style="vertical-align:top"><p>-18.3</p></td></tr><tr><td style="vertical-align:top"><p>Atorvastatin 20 mg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 480</p></td><td style="vertical-align:top"><p>-6.4<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>-9.5<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>-6.0<sup>&para;</sup></p></td><td style="vertical-align:top"><p>-3.9</p></td><td style="vertical-align:top"><p>-1.1</p></td><td style="vertical-align:top"><p>-8.1<sup>&sect;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Rosuvastatin 10 mg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 939</p></td><td style="vertical-align:top"><p>-7.7<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>-13.0<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>-6.9<sup>#</sup></p></td><td style="vertical-align:top"><p>-1.1</p></td><td style="vertical-align:top"><p>+1.1</p></td><td style="vertical-align:top"><p>-10.6<sup>&sect;</sup></p></td></tr></tbody></table><p><strong>Phase II</strong></p><p>Switched from atorvastatin 20 mg</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>ATOZET 10/20</p></td><td style="vertical-align:top"><p>124</p></td><td style="vertical-align:top"><p>-10.7</p></td><td style="vertical-align:top"><p>-17.4</p></td><td style="vertical-align:top"><p>-9.8</p></td><td style="vertical-align:top"><p>-5.9</p></td><td style="vertical-align:top"><p>+0.7</p></td><td style="vertical-align:top"><p>-15.1</p></td></tr><tr><td style="vertical-align:top"><p>Atorvastatin 40 mg</p></td><td style="vertical-align:top"><p>124</p></td><td style="vertical-align:top"><p>-3.8 <sup>&THORN;</sup></p></td><td style="vertical-align:top"><p>-6.9 <sup>&THORN;</sup></p></td><td style="vertical-align:top"><p>-5.4</p></td><td style="vertical-align:top"><p>-3.1</p></td><td style="vertical-align:top"><p>+1.7</p></td><td style="vertical-align:top"><p>-5.8 <sup>&THORN;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Switched from</p><p>rosuvastatin 10 mg</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ATOZET 10/20</p></td><td style="vertical-align:top"><p>231</p></td><td style="vertical-align:top"><p>-11.8</p></td><td style="vertical-align:top"><p>-17.1</p></td><td style="vertical-align:top"><p>-11.9</p></td><td style="vertical-align:top"><p>-10.2</p></td><td style="vertical-align:top"><p>+0.1</p></td><td style="vertical-align:top"><p>-16.2</p></td></tr><tr><td style="vertical-align:top"><p>Rosuvastatin 20 mg</p></td><td style="vertical-align:top"><p>205</p></td><td style="vertical-align:top"><p>-4.5<sup>&THORN;</sup></p></td><td style="vertical-align:top"><p>-7.5 <sup>&THORN;</sup></p></td><td style="vertical-align:top"><p>-4.1<sup>&THORN;</sup></p></td><td style="vertical-align:top"><p>-3.2<sup>&szlig;</sup></p></td><td style="vertical-align:top"><p>+0.8</p></td><td style="vertical-align:top"><p>-6.4 <sup>&THORN;</sup></p></td></tr></tbody></table><p>* Co-administered ezetimibe and atorvastatin equivalent to ATOZET 10/10 or ATOZET 10/20</p><p>&nbsp;</p><p>&dagger; M-Estimates (based on the method of Huber; 95% CI and p-value were obtained from fitting a robust Regression model with terms for treatment and baseline)</p><p>&Dagger; Geometric mean percent changes from baseline in TG were calculated based on back-transformation via exponentiation of the model-based least square (LS) means and expressed as (geometric mean &ndash; 1) multiplied by 100</p><p>&sect; p&lt;0.001 versus ATOZET 10/10</p><p>&para;&nbsp; p&lt;0.01 versus ATOZET 10/10 #&nbsp; p&lt;0.05 versus ATOZET 10/10 &THORN; p&lt;0.001 versus ATOZET 10/20 &szlig; p&lt;0.05 versus ATOZET 10/20</p><p>&nbsp;</p><p>Table 5 does not contain data comparing the effects of ATOZET 10/10 or 10/20 to doses higher than atorvastatin 40 mg or rosuvastatin 20 mg.</p><p>&nbsp;</p><p>In a placebo-controlled study, the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study, patients with an acute coronary syndrome (non Q-wave MI or unstable angina) were randomised to receive atorvastatin 80 mg/day (n=1538) or placebo (n=1548). Treatment was initiated during the acute phase after hospital admission and lasted for 16 weeks. Atorvastatin 80 mg/day provided a 16% (p=0.048) reduction in risk of the combined primary endpoint: death from any cause, nonfatal MI, resuscitated cardiac arrest, or angina pectoris with evidence of myocardial ischaemia requiring hospitalisation. This was mainly due to a 26% reduction in re-hospitalisation for angina pectoris with evidence of myocardial ischaemia (p=0.018).</p><p>&nbsp;</p><p>ATOZET contains atorvastatin. In a placebo-controlled study, the Anglo-Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm (ASCOT-LLA), the effect of atorvastatin 10 mg on fatal and non-fatal CHD was assessed in 10,305 hypertensive patients, 40-80 years old, with TC levels &le;6.5 mmol/L and at least three cardiovascular risk factors. Patients were followed for a median duration of 3.3 years. Atorvastatin 10 mg significantly (p&lt;0.001) reduced the relative risk for: fatal CHD plus nonfatal MI by 36% (absolute risk reduction = 1.1%); total cardiovascular events and revascularisation procedures by 20% (absolute risk reduction = 1.9%); and total coronary events by 29% (absolute risk reduction = 1.4%).</p><p>&nbsp;</p><p>In a placebo-controlled study, the Collaborative Atorvastatin Diabetes Study (CARDS), the effect of atorvastatin 10 mg on cardiovascular disease (CVD) endpoints was assessed in 2838 patients, 40-75 years old, with type 2 diabetes, one or more cardiovascular risk factors, LDL &le;4.1 mmol/L, and TG</p><p>&le;6.8 mmol/L. Patients were followed for a median duration of 3.9 years. Atorvastatin 10 mg significantly (p&lt;0.05) reduced: the rate of major cardiovascular events by 37% (absolute risk reduction = 3.2%); the risk of stroke by 48% (absolute risk reduction = 1.3%); and the risk of MI by 42% (absolute risk reduction = 1.9%).</p><p>&nbsp;</p><p><strong><em>Prevention of Cardiovascular Events</em></strong></p><p>In an ezetimibe/simvastatin, multicenter, randomised, double-blind, active-control study, 18,144 patients enrolled within 10 days of hospitalisation for acute coronary syndrome (ACS; either acute myocardial infarction [MI] or unstable angina [UA]). All patients were randomised in a 1:1 ratio to receive either ezetimibe/simvastatin 10/40 mg (n=9067) or simvastatin 40 mg (n=9077) and followed for a median of</p><p>6.0 years.</p><p>&nbsp;</p><p>Patients had a mean age of 63.6 years; 76% were male, 84% were Caucasian, and 27% were diabetic. The average LDL-C value at the time of study qualifying event was 80 mg/dL (2.1 mmol/L) for those on lipid- lowering therapy (n=6390) and 101 mg/dL (2.6 mmol/L) for those not on previous lipid-lowering therapy (n=11594). Prior to the hospitalisation for the qualifying ACS event, 34% of the patients were on statin therapy. At one-year, the average LDL-C for patients continuing on therapy was 53.2 mg/dL</p><p>(1.4 mmol/L) for the ezetimibe/simvastatin group and 69.9 mg/dL (1.8 mmol/L) for the simvastatin monotherapy group.</p><p>&nbsp;</p><p>The primary endpoint was a composite consisting of cardiovascular death, major coronary events (MCE; defined as non-fatal myocardial infarction, documented unstable angina that required hospitalisation, or any coronary revascularisation procedure occurring at least 30 days after randomised treatment assignment) and non-fatal stroke. The study demonstrated that treatment with ezetimibe/simvastatin provided incremental benefit in reducing the primary composite endpoint of cardiovascular death, MCE, and non-fatal stroke compared with simvastatin alone (relative risk reduction of 6.4%, p=0.016). The primary endpoint occurred in 2572 of 9067 patients (7-year Kaplan-Meier [KM] rate 32.72%) in the ezetimibe/simvastatin group and 2742 of 9077 patients (7-year KM rate 34.67%) in the simvastatin alone group. (See Figure 1 and Table 6.) This incremental benefit is expected to be similar with co- administration of ezetimibe and atorvastatin. Total mortality was unchanged in this high risk group.</p><p>&nbsp;</p><p>There was an overall benefit for all strokes; however there was a small non-significant increase in haemorrhagic stroke in the ezetimibe-simvastatin group compared with simvastatin alone. The risk of haemorrhagic stroke for ezetimibe co-administered with higher potency statins in long-term outcome studies has not been evaluated.</p><p>&nbsp;</p><p>The treatment effect of ezetimibe/simvastatin was generally consistent with the overall results across many subgroups, including sex, age, race, medical history of diabetes mellitus, baseline lipid levels, prior statin therapy, prior stroke, and hypertension.</p><p>&nbsp;</p><p><img src="data:image/png;base64,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" alt="" width="1196" height="885" vspace="0" hspace="0" border="0" style="width:1196px;height:885px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p>&nbsp;</p><p><img src="data:image/png;base64,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" alt="" width="809" height="419" vspace="0" hspace="0" border="0" style="width:809px;height:419px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p><em>Homozygous Familial Hypercholesterolaemia (HoFH)</em></p><p>A double-blind, randomised, 12-week study was performed in patients with a clinical and/or genotypic diagnosis of HoFH. Data were analysed from a subgroup of patients (n=36) receiving atorvastatin 40 mg at baseline. Increasing the dose of atorvastatin from 40 to 80 mg (n=12) produced a reduction of LDL-C of 2% from baseline on atorvastatin 40 mg. Co-administered ezetimibe and atorvastatin equivalent to ATOZET (10/40 and 10/80 pooled, n=24), produced a reduction of LDL-C of 19% from baseline on atorvastatin 40 mg. In those patients co-administered ezetimibe and atorvastatin equivalent to ATOZET (10/80, n=12), a reduction of LDL-C of 25% from baseline on atorvastatin 40 mg was produced.</p><p>&nbsp;</p><p>After completing the 12-week study, eligible patients (n=35), who were receiving atorvastatin 40 mg at baseline, were assigned to co-administered ezetimibe and atorvastatin equivalent to ATOZET 10/40 for up to an additional 24 months. Following at least 4 weeks of treatment, the atorvastatin dose could be doubled to a maximum dose of 80 mg. At the end of the 24 months, ATOZET (10/40 and 10/80 pooled) produced a reduction of LDL-C that was consistent with that seen in the 12-week study.</p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with ATOZET in all subsets of the paediatric population in the treatments of hypercholesterolaemia and mixed hyperlipidaemia (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>ATOZET</em></p><p>ATOZET has been shown to be bioequivalent to co-administration of corresponding doses of ezetimibe and atorvastatin tablets.</p><p>&nbsp;</p><p><u>Absorption</u></p><p><em>ATOZET</em></p><p>&nbsp;</p><p>The effects of a high-fat meal on the pharmacokinetics of ezetimibe and atorvastatin when administered as ATOZET tablets are comparable to those reported for the individual tablets.</p><p>&nbsp;</p><p><em>Ezetimibe</em></p><p>After oral administration, ezetimibe is rapidly absorbed and extensively conjugated to a pharmacologically active phenolic glucuronide (ezetimibe-glucuronide). Mean maximum plasma concentrations (C<sub>max</sub>) occur within 1 to 2 hours for ezetimibe-glucuronide and 4 to 12 hours for ezetimibe. The absolute bioavailability of ezetimibe cannot be determined as the compound is virtually insoluble in aqueous media suitable for injection.</p><p>&nbsp;</p><p>Concomitant food administration (high-fat or non-fat meals) had no effect on the oral bioavailability of ezetimibe when administered as 10-mg tablets.</p><p>&nbsp;</p><p><em>Atorvastatin</em></p><p>Atorvastatin is rapidly absorbed after oral administration; maximum plasma concentrations (C<sub>max</sub>) occur within 1 to 2 hours. Extent of absorption increases in proportion to atorvastatin dose. After oral administration, atorvastatin film-coated tablets are 95% to 99% bioavailable compared to the oral solution. The absolute bioavailability of atorvastatin is approximately 12% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic availability is attributed to presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism.</p><p>&nbsp;</p><p><u>Distribution</u></p><p><em>Ezetimibe</em></p><p>Ezetimibe and ezetimibe-glucuronide are bound 99.7% and 88 to 92% to human plasma proteins, respectively.</p><p>&nbsp;</p><p><em>Atorvastatin</em></p><p>Mean volume of distribution of atorvastatin is approximately 381 l. Atorvastatin is &ge;98% bound to plasma proteins.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p><em>Ezetimibe</em></p><p>Ezetimibe is metabolised primarily in the small intestine and liver via glucuronide conjugation (a phase II reaction) with subsequent biliary excretion. Minimal oxidative metabolism (a phase I reaction) has been observed in all species evaluated. Ezetimibe and ezetimibe-glucuronide are the major drug-derived compounds detected in plasma, constituting approximately 10 to 20% and 80 to 90% of the total drug in plasma, respectively. Both ezetimibe and ezetimibe-glucuronide are slowly eliminated from plasma with evidence of significant enterohepatic recycling. The half-life for ezetimibe and ezetimibe-glucuronide is approximately 22 hours.</p><p>&nbsp;</p><p><em>Atorvastatin</em></p><p>Atorvastatin is metabolised by cytochrome P450 3A4 to ortho- and parahydroxylated derivatives and various beta-oxidation products. Apart from other pathways these products are further metabolised via glucuronidation. <em>In vitro</em>, inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites.</p><p>&nbsp;</p><p><u>Elimination</u></p><p><em>Ezetimibe</em></p><p>Following oral administration of <sup>14</sup>C-ezetimibe (20 mg) to human subjects, total ezetimibe accounted for approximately 93% of the total radioactivity in plasma. Approximately 78% and 11% of the administered</p><p>&nbsp;</p><p>radioactivity were recovered in the faeces and urine, respectively, over a 10-day collection period. After 48 hours, there were no detectable levels of radioactivity in the plasma.</p><p>&nbsp;</p><p><em>Atorvastatin</em></p><p>Atorvastatin is eliminated primarily in bile following hepatic and/or extrahepatic metabolism. However, the medicinal product does not appear to undergo significant enterohepatic recirculation. Mean plasma elimination half-life of atorvastatin in humans is approximately 14 hours. The half-life of inhibitory activity for HMG-CoA reductase is approximately 20 to 30 hours due to the contribution of active metabolites.</p><p>&nbsp;</p><p>Atorvastatin is a substrate of the hepatic transporters, organic anion-transporting polypeptide 1B1 (OATP1B1) and 1B3 (OATP1B3) transporter. Metabolites of atorvastatin are substrates of OATP1B1. Atorvastatin is also identified as a substrate of the efflux transporters multi-drug resistance protein 1 (MDR1) and breast cancer resistance protein (BCRP), which may limit the intestinal absorption and biliary clearance of atorvastatin.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p><em>Ezetimibe</em></p><p>The pharmacokinetics of ezetimibe are similar between children &nbsp;&ge; 6 years and adults. Pharmacokinetic data in the paediatric population &lt; 6 years of age are not available. Clinical experience in paediatric and adolescent patients includes patients with HoFH, HeFH, or sitosterolaemia.</p><p>&nbsp;</p><p><em>Atorvastatin</em></p><p>In an open-label, 8-week study, Tanner Stage 1 (n=15) and Tanner Stage 2 (n=24) paediatric patients (ages 6-17 years) with heterozygous familial hypercholesterolaemia and baseline LDL-C &ge; 4 mmol/L were treated with 5 or 10 mg of chewable or 10 or 20 mg of film-coated atorvastatin tablets once daily, respectively. Body weight was the only significant covariate in atorvastatin population PK model.</p><p>Apparent oral clearance of atorvastatin in paediatric subjects appeared similar to adults when scaled allometrically by body weight. Consistent decreases in LDL-C and TC were observed over the range of atorvastatin and o-hydroxyatorvastatin exposures.</p><p>&nbsp;</p><p><u>Elderly</u></p><p><em>Ezetimibe</em></p><p>Plasma concentrations for total ezetimibe are about 2-fold higher in the elderly (&sup3;65 years) than in the young (18 to 45 years). LDL-C reduction and safety profile are comparable between elderly and younger subjects treated with ezetimibe.</p><p>&nbsp;</p><p><em>Atorvastatin</em></p><p>Plasma concentrations of atorvastatin and its active metabolites are higher in healthy elderly subjects than in young adults while the lipid effects were comparable to those seen in younger patient populations.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p><em>Ezetimibe</em></p><p>After a single 10-mg dose of ezetimibe, the mean AUC for total ezetimibe was increased approximately 1.7-fold in patients with mild hepatic insufficiency (Child-Pugh score 5 or 6), compared to healthy subjects. In a 14-day, multiple-dose study (10 mg daily) in patients with moderate hepatic insufficiency (Child-Pugh score 7 to 9), the mean AUC for total ezetimibe was increased approximately 4-fold on&nbsp; Day 1 and Day 14 compared to healthy subjects. No dose adjustment is necessary for patients with mild hepatic insufficiency. Due to the unknown effects of the increased exposure to ezetimibe in patients with moderate or severe (Child-Pugh score &gt; 9) hepatic insufficiency, ezetimibe is not recommended in these patients (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p><em>Atorvastatin</em></p><p>Plasma concentrations of atorvastatin and its active metabolites are markedly increased (approx. 16-fold in C<sub>max</sub> and approx. 11-fold in AUC) in patients with chronic alcoholic liver disease (Child-Pugh B).</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p><em>Ezetimibe</em></p><p>After a single 10-mg dose of ezetimibe in patients with severe renal disease (n=8; mean CrCl</p><p>&pound;30 mL/min/1.73 m<sup>2</sup>), the mean AUC for total ezetimibe was increased approximately 1.5-fold, compared to healthy subjects (n=9).</p><p>&nbsp;</p><p>An additional patient in this study (post-renal transplant and receiving multiple medicinal products, including ciclosporin) had a 12-fold greater exposure to total ezetimibe.</p><p>&nbsp;</p><p><em>Atorvastatin</em></p><p>Renal disease has no influence on the plasma concentrations or lipid effects of atorvastatin and its active metabolites.</p><p>&nbsp;</p><p><u>Gender</u></p><p><em>Ezetimibe</em></p><p>Plasma concentrations for total ezetimibe are slightly higher (approximately 20%) in women than in men. LDL-C reduction and safety profile are comparable between men and women treated with ezetimibe.</p><p>&nbsp;</p><p><em>Atorvastatin</em></p><p>Concentrations of atorvastatin and its active metabolites in women differ from those in men (women: approx. 20% higher for C<sub>max</sub> and approx. 10% lower for AUC). These differences were of no clinical significance, resulting in no clinically significant differences in lipid effects among men and women. <u>SLCO1B1 polymorphism</u></p><p>&nbsp;</p><p><em>Atorvastatin</em></p><p>Hepatic uptake of all HMG-CoA reductase inhibitors, including atorvastatin, involves the OATP1B1 transporter. In patients with SLCO1B1 polymorphism there is a risk of increased exposure of atorvastatin, which may lead to an increased risk of rhabdomyolysis (see section 4.4). Polymorphism in the gene encoding OATP1B1 (SLCO1B1 c.521CC) is associated with a 2.4-fold higher atorvastatin exposure (AUC) than in individuals without this genotype variant (c.521TT). A genetically impaired hepatic uptake of atorvastatin is also possible in these patients. Possible consequences for the efficacy are unknown</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><em>ATOZET</em></p><p>In three-month co-administration studies in rats and dogs with ezetimibe and atorvastatin, the toxic effects observed were essentially those typically associated with statins. The statin-like histopathologic findings were limited to the liver. Some of the toxic effects were more pronounced than those observed during treatment with statins alone. This is attributed to pharmacokinetic and/or pharmacodynamic interactions following co-administration.</p><p>&nbsp;</p><p>The co-administration of ezetimibe and atorvastatin in pregnant rats indicated that there was a test article- related increase in the skeletal variation &ldquo;reduced ossification of the sternebrae&rdquo; in the high dose (1000/108.6 mg/kg) ezetimibe/atorvastatin group. This may be related to the observed decrease in foetal body weights. In pregnant rabbits a low incidence of skeletal deformities (fused sternebrae, fused caudal vertebrae and asymmetrical sternebrae variation) were observed.</p><p>&nbsp;</p><p>In a series of <em>in vivo </em>and <em>in vitro </em>assays, ezetimibe, given alone or co-administered with atorvastatin, exhibited no genotoxic potential.</p><p>&nbsp;</p><p><em>Ezetimibe</em></p><p>Animal studies on the chronic toxicity of ezetimibe identified no target organs for toxic effects. In dogs treated for four weeks with ezetimibe (&ge;0.03 mg/kg/day) the cholesterol concentration in the cystic bile was increased by a factor of 2.5 to 3.5. However, in a one-year study on dogs given doses of up to</p><p>300 mg/kg/day no increased incidence of cholelithiasis or other hepatobiliary effects were observed. The significance of these data for humans is not known. A lithogenic risk associated with the therapeutic use of ezetimibe cannot be ruled out.</p><p>&nbsp;</p><p>Long-term carcinogenicity tests on ezetimibe were negative.</p><p>&nbsp;</p><p>Ezetimibe had no effect on the fertility of male or female rats, nor was it found to be teratogenic in rats or rabbits, nor did it affect prenatal or postnatal development. Ezetimibe crossed the placental barrier in pregnant rats and rabbits given multiple doses of 1000 mg/kg/day.</p><p>&nbsp;</p><p><em>Atorvastatin</em></p><p>Atorvastatin was negative for mutagenic and clastogenic potential in a battery of 4 <em>in vitro </em>tests and 1 <em>in vivo </em>assay. Atorvastatin was not found to be carcinogenic in rats, but high doses in mice (resulting in 6-11 fold the AUC0-24h reached in humans at the highest recommended dose) showed hepatocellular adenomas in males and hepatocellular carcinomas in females. There is evidence from animal experimental studies that HMG-CoA reductase inhibitors may affect the development of embryos or foetuses. In rats, rabbits, and dogs atorvastatin had no effect on fertility and was not teratogenic, however, at maternally toxic doses foetal toxicity was observed in rats and rabbits. The development of the rat offspring was delayed and post-natal survival reduced during exposure of the dams to high doses of atorvastatin. In rats, there is evidence of placental transfer. In rats, plasma concentrations of atorvastatin are similar to those in milk. It is not known whether atorvastatin or its metabolites are excreted in human milk.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p><u>Tablet core</u> Ezetimibe Layer</p><p>Croscarmellose sodium Lactose monohydrate Magnesium stearate Cellulose, microcrystalline Povidone</p><p>Sodium laurilsulphate</p><p>&nbsp;</p><p>Atorvastatin Layer</p><p>Cellulose, microcrystalline Lactose monohydrate Hydroxypropylcellulose Croscarmellose sodium Polysorbate 80</p><p>&nbsp;</p><p>Calcium carbonate Magnesium stearate Silica, colloidal anhydrous</p><p>&nbsp;</p><p><u>Film coating</u></p><p>Hypromellose Macrogol 8000</p><p>Titanium dioxide (E171) Talc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg; C</p><p>Store in the original package in order to protect from oxygen.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>ATOZET 10 mg/10 mg</u><u>, 10 mg/20 mg and 10 mg/</u><u>40</u><u> mg</u></p><p>Packs of 10, 30, 90, and 100 film-coated tablets in nitrogen-purged aluminium/aluminium (oPA-Al-PVC cavity with Al lidding) blisters.</p><p>&nbsp;</p><p>Packs of 30 x 1 and 45 x 1 film-coated tablets in unit dose nitrogen-purged aluminium/aluminium (oPA- Al-PVC cavity with Al lidding) blisters.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder
Merck Sharp & Dohme Ltd Hertford Road,
Hoddesdon Hertfordshire EN11 9BU

Manufacturer:
MSD International GmbH (Puerto Rico Branch) LLC, 
State Road 183, PRIDCO Industrial Park,
Las Piedras, Puerto Rico 00771

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
12 September 2020 

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>